{
  "doc_id": "18",
  "paragraphs": [
    {
      "paragraph_id": "0",
      "paragraph": "盘点降糖药物的中国指南/共识(下)",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "盘点降糖药物的中国指南/共识(下)",
          "start_idx": 0,
          "end_idx": 17,
          "entities": [],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "1",
      "paragraph": "近几年，国外新药进入中国市场的速度似乎逐渐加快，这些新药无疑给血糖管理增添了新的选择，基于国内外的研究证据，国内学术组织已经发布了一些针对这些新药的指南或共识，这有助于规范用临床应用，下面就让我们一起去了解这些新型降糖药。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "近几年，国外新药进入中国市场的速度似乎逐渐加快，这些新药无疑给血糖管理增添了新的选择，基于国内外的研究证据，国内学术组织已经发布了一些针对这些新药的指南或共识，这有助于规范用临床应用，下面就让我们一起去了解这些新型降糖药。",
          "start_idx": 0,
          "end_idx": 111,
          "entities": [
            {
              "entity_id": "T0",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 31,
              "end_idx": 33
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "2",
      "paragraph": "现在，我国临床上可供选择的降糖药物已达到九种，其中二肽基肽酶IV(DPP- 4)抑制剂、胰高血糖素样肽1(GLP-1)受体激动剂和钠-葡萄糖共转运蛋白2(SGLT-2)抑制剂是最近几年刚刚进入我国，但由于作用机制不同于传统的降糖药物，迅速成为热门药物。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "现在，我国临床上可供选择的降糖药物已达到九种，其中二肽基肽酶IV(DPP- 4)抑制剂、胰高血糖素样肽1(GLP-1)受体激动剂和钠-葡萄糖共转运蛋白2(SGLT-2)抑制剂是最近几年刚刚进入我国，但由于作用机制不同于传统的降糖药物，迅速成为热门药物。",
          "start_idx": 0,
          "end_idx": 126,
          "entities": [
            {
              "entity_id": "T1",
              "entity": "二肽基肽酶IV(DPP- 4)抑制剂",
              "entity_type": "Drug",
              "start_idx": 25,
              "end_idx": 43
            },
            {
              "entity_id": "T2",
              "entity": "胰高血糖素样肽1(GLP-1)受体激动剂",
              "entity_type": "Drug",
              "start_idx": 44,
              "end_idx": 64
            },
            {
              "entity_id": "T3",
              "entity": "钠-葡萄糖共转运蛋白2(SGLT-2)抑制剂",
              "entity_type": "Drug",
              "start_idx": 65,
              "end_idx": 87
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "3",
      "paragraph": "DPP-4抑制剂：(《基于胰高血糖素样肽1降糖药物的临床应用共识》/《基于肠促胰素的药物治疗临床应用的快速建议指南》)",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "DPP-4抑制剂：(《基于胰高血糖素样肽1降糖药物的临床应用共识》/《基于肠促胰素的药物治疗临床应用的快速建议指南》)",
          "start_idx": 0,
          "end_idx": 59,
          "entities": [
            {
              "entity_id": "T4",
              "entity": "DPP-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 8
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "4",
      "paragraph": "胃肠道是机体重要的内分泌器官，其分泌的肠促胰素所引起的胰岛素分泌约占全部胰岛素分泌量的50%~70%，而且肠促胰素刺激胰岛素分泌的作用具有葡萄糖浓度依赖的特点，故在调节血糖的同时，引起低血糖的风险很低。正因为如此，人们研发出了模拟肠促胰素的GLP-1受体激动剂和延缓肠促胰素降解的DPP- 4抑制剂。目前国内已经上市了两种GLP-1受体激动剂(艾塞那肽和利拉鲁肽)和5种DPP-4抑制剂(西格列汀、维格列汀、沙格列汀、利格列汀和阿格列汀)(见表1)。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "胃肠道是机体重要的内分泌器官，其分泌的肠促胰素所引起的胰岛素分泌约占全部胰岛素分泌量的50%~70%，而且肠促胰素刺激胰岛素分泌的作用具有葡萄糖浓度依赖的特点，故在调节血糖的同时，引起低血糖的风险很低。",
          "start_idx": 0,
          "end_idx": 101,
          "entities": [
            {
              "entity_id": "T5",
              "entity": "低血糖",
              "entity_type": "Disease",
              "start_idx": 92,
              "end_idx": 95
            },
            {
              "entity_id": "T6",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 84,
              "end_idx": 86
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R0",
              "head_entity_id": "T6",
              "tail_entity_id": "T5"
            }
          ]
        },
        {
          "sentence_id": "1",
          "sentence": "正因为如此，人们研发出了模拟肠促胰素的GLP-1受体激动剂和延缓肠促胰素降解的DPP- 4抑制剂。",
          "start_idx": 101,
          "end_idx": 150,
          "entities": [
            {
              "entity_id": "T7",
              "entity": "GLP-1受体激动剂",
              "entity_type": "Drug",
              "start_idx": 19,
              "end_idx": 29
            },
            {
              "entity_id": "T8",
              "entity": "DPP- 4抑制剂",
              "entity_type": "Drug",
              "start_idx": 39,
              "end_idx": 48
            }
          ],
          "relations": []
        },
        {
          "sentence_id": "2",
          "sentence": "目前国内已经上市了两种GLP-1受体激动剂(艾塞那肽和利拉鲁肽)和5种DPP-4抑制剂(西格列汀、维格列汀、沙格列汀、利格列汀和阿格列汀)(见表1)。",
          "start_idx": 150,
          "end_idx": 225,
          "entities": [
            {
              "entity_id": "T9",
              "entity": "GLP-1受体激动剂",
              "entity_type": "Drug",
              "start_idx": 11,
              "end_idx": 21
            },
            {
              "entity_id": "T10",
              "entity": "艾塞那肽",
              "entity_type": "Drug",
              "start_idx": 22,
              "end_idx": 26
            },
            {
              "entity_id": "T11",
              "entity": "利拉鲁肽",
              "entity_type": "Drug",
              "start_idx": 27,
              "end_idx": 31
            },
            {
              "entity_id": "T12",
              "entity": "DPP-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 35,
              "end_idx": 43
            },
            {
              "entity_id": "T13",
              "entity": "西格列汀",
              "entity_type": "Drug",
              "start_idx": 44,
              "end_idx": 48
            },
            {
              "entity_id": "T14",
              "entity": "维格列汀",
              "entity_type": "Drug",
              "start_idx": 49,
              "end_idx": 53
            },
            {
              "entity_id": "T15",
              "entity": "沙格列汀",
              "entity_type": "Drug",
              "start_idx": 54,
              "end_idx": 58
            },
            {
              "entity_id": "T16",
              "entity": "利格列汀",
              "entity_type": "Drug",
              "start_idx": 59,
              "end_idx": 63
            },
            {
              "entity_id": "T17",
              "entity": "阿格列汀",
              "entity_type": "Drug",
              "start_idx": 64,
              "end_idx": 68
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "5",
      "paragraph": "中华医学会糖尿病学分会(CDS)在2014年发布了《基于胰高血糖素样肽1降糖药物的临床应用共识》(简称“临床应用共识”)；中华医学会内分泌学分会与中国药学会医院药学专业委员会在2015年年底联合发布了《基于肠促胰素的药物治疗临床应用的快速建议指南》(简称“快速建议指南”)，该指南计划于2018年进行更新，届时可能会根据新的中国证据做出一些调整。DPP-4抑制剂在2017年才被纳入医保乙类药物(即需要部分自费)，所以临床上更多地是在大城市的大医院使用，或是在其他降糖药物效果不佳时才被使用，所以在我国的糖尿病指南中的治疗地位要比快速建议指南中的地位略低一些。以下内容我们将仅仅客观分析现有证据，具体到临床应用，大家还是需要和医生共同商定。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "中华医学会糖尿病学分会(CDS)在2014年发布了《基于胰高血糖素样肽1降糖药物的临床应用共识》(简称“临床应用共识”)；中华医学会内分泌学分会与中国药学会医院药学专业委员会在2015年年底联合发布了《基于肠促胰素的药物治疗临床应用的快速建议指南》(简称“快速建议指南”)，该指南计划于2018年进行更新，届时可能会根据新的中国证据做出一些调整。",
          "start_idx": 0,
          "end_idx": 173,
          "entities": [
            {
              "entity_id": "T18",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 5,
              "end_idx": 8
            }
          ],
          "relations": []
        },
        {
          "sentence_id": "1",
          "sentence": "DPP-4抑制剂在2017年才被纳入医保乙类药物(即需要部分自费)，所以临床上更多地是在大城市的大医院使用，或是在其他降糖药物效果不佳时才被使用，所以在我国的糖尿病指南中的治疗地位要比快速建议指南中的地位略低一些。",
          "start_idx": 173,
          "end_idx": 280,
          "entities": [
            {
              "entity_id": "T19",
              "entity": "DPP-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 8
            },
            {
              "entity_id": "T20",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 79,
              "end_idx": 82
            }
          ],
          "relations": []
        },
        {
          "sentence_id": "2",
          "sentence": "以下内容我们将仅仅客观分析现有证据，具体到临床应用，大家还是需要和医生共同商定。",
          "start_idx": 280,
          "end_idx": 320,
          "entities": [],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "6",
      "paragraph": "适用人群",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "适用人群",
          "start_idx": 0,
          "end_idx": 4,
          "entities": [],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "7",
      "paragraph": "临床应用共识指出，DPP-4抑制剂适用于成人2型糖尿病患者的血糖控制。目前国内批准该类药物的适应证为：西格列汀可配合饮食控制与运动，进行单药或与二甲双胍联合使用治疗改善血糖控制；沙格列汀和阿格列汀可在饮食和运动基础上单药治疗，亦可在单独使用二甲双胍血糖控制不佳时与二甲双胍联合使用；维格列汀在二甲双胍作为单药治疗用至最大耐受剂量仍不能有效控制血糖时，与二甲双胍联合使用；利格列汀可配合饮食控制和运动，与二甲双胍和磺脲类药物联合使用改善血糖控制。临床应用共识还强调，DPP-4抑制剂不能用于1型糖尿病或糖尿病酮症酸中毒的患者；不推荐用于妊娠期、哺乳期妇女以及儿童。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "临床应用共识指出，DPP-4抑制剂适用于成人2型糖尿病患者的血糖控制。",
          "start_idx": 0,
          "end_idx": 35,
          "entities": [
            {
              "entity_id": "T21",
              "entity": "DPP-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 9,
              "end_idx": 17
            },
            {
              "entity_id": "T35",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 22,
              "end_idx": 27
            },
            {
              "entity_id": "T36",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 22,
              "end_idx": 24
            },
            {
              "entity_id": "T37",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 30,
              "end_idx": 32
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R1",
              "head_entity_id": "T21",
              "tail_entity_id": "T35"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R2",
              "head_entity_id": "T36",
              "tail_entity_id": "T35"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R3",
              "head_entity_id": "T37",
              "tail_entity_id": "T35"
            }
          ]
        },
        {
          "sentence_id": "1",
          "sentence": "目前国内批准该类药物的适应证为：西格列汀可配合饮食控制与运动，进行单药或与二甲双胍联合使用治疗改善血糖控制；沙格列汀和阿格列汀可在饮食和运动基础上单药治疗，亦可在单独使用二甲双胍血糖控制不佳时与二甲双胍联合使用；维格列汀在二甲双胍作为单药治疗用至最大耐受剂量仍不能有效控制血糖时，与二甲双胍联合使用；利格列汀可配合饮食控制和运动，与二甲双胍和磺脲类药物联合使用改善血糖控制。",
          "start_idx": 35,
          "end_idx": 222,
          "entities": [
            {
              "entity_id": "T22",
              "entity": "西格列汀",
              "entity_type": "Drug",
              "start_idx": 16,
              "end_idx": 20
            },
            {
              "entity_id": "T23",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 37,
              "end_idx": 41
            },
            {
              "entity_id": "T24",
              "entity": "沙格列汀",
              "entity_type": "Drug",
              "start_idx": 54,
              "end_idx": 58
            },
            {
              "entity_id": "T25",
              "entity": "阿格列汀",
              "entity_type": "Drug",
              "start_idx": 59,
              "end_idx": 63
            },
            {
              "entity_id": "T26",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 85,
              "end_idx": 89
            },
            {
              "entity_id": "T27",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 97,
              "end_idx": 101
            },
            {
              "entity_id": "T28",
              "entity": "维格列汀",
              "entity_type": "Drug",
              "start_idx": 106,
              "end_idx": 110
            },
            {
              "entity_id": "T29",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 111,
              "end_idx": 115
            },
            {
              "entity_id": "T30",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 141,
              "end_idx": 145
            },
            {
              "entity_id": "T31",
              "entity": "利格列汀",
              "entity_type": "Drug",
              "start_idx": 150,
              "end_idx": 154
            },
            {
              "entity_id": "T32",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 166,
              "end_idx": 170
            },
            {
              "entity_id": "T33",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 171,
              "end_idx": 176
            },
            {
              "entity_id": "T38",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 49,
              "end_idx": 51
            },
            {
              "entity_id": "T39",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 89,
              "end_idx": 91
            },
            {
              "entity_id": "T40",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 136,
              "end_idx": 138
            },
            {
              "entity_id": "T41",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 182,
              "end_idx": 184
            },
            {
              "entity_id": "T42",
              "entity": "饮食控制",
              "entity_type": "Treatment",
              "start_idx": 23,
              "end_idx": 27
            },
            {
              "entity_id": "T43",
              "entity": "运动",
              "entity_type": "Treatment",
              "start_idx": 28,
              "end_idx": 30
            },
            {
              "entity_id": "T44",
              "entity": "饮食",
              "entity_type": "Treatment",
              "start_idx": 65,
              "end_idx": 67
            },
            {
              "entity_id": "T45",
              "entity": "运动",
              "entity_type": "Treatment",
              "start_idx": 68,
              "end_idx": 70
            },
            {
              "entity_id": "T46",
              "entity": "饮食控制",
              "entity_type": "Treatment",
              "start_idx": 157,
              "end_idx": 161
            },
            {
              "entity_id": "T47",
              "entity": "运动",
              "entity_type": "Treatment",
              "start_idx": 162,
              "end_idx": 164
            },
            {
              "entity_id": "T48",
              "entity": "控制不佳",
              "entity_type": "Test_Value",
              "start_idx": 91,
              "end_idx": 95
            }
          ],
          "relations": []
        },
        {
          "sentence_id": "2",
          "sentence": "临床应用共识还强调，DPP-4抑制剂不能用于1型糖尿病或糖尿病酮症酸中毒的患者；不推荐用于妊娠期、哺乳期妇女以及儿童。",
          "start_idx": 222,
          "end_idx": 281,
          "entities": [
            {
              "entity_id": "T34",
              "entity": "DPP-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 10,
              "end_idx": 18
            },
            {
              "entity_id": "T49",
              "entity": "1型糖尿病",
              "entity_type": "Disease",
              "start_idx": 22,
              "end_idx": 27
            },
            {
              "entity_id": "T50",
              "entity": "糖尿病酮症酸中毒",
              "entity_type": "Disease",
              "start_idx": 28,
              "end_idx": 36
            },
            {
              "entity_id": "T51",
              "entity": "1型",
              "entity_type": "Class",
              "start_idx": 22,
              "end_idx": 24
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R4",
              "head_entity_id": "T51",
              "tail_entity_id": "T49"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "8",
      "paragraph": "临床用法",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "临床用法",
          "start_idx": 0,
          "end_idx": 4,
          "entities": [],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "9",
      "paragraph": "(1)起始用药",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(1)起始用药",
          "start_idx": 0,
          "end_idx": 7,
          "entities": [],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "10",
      "paragraph": "快速建议指南推荐DPP-4抑制剂作为2型糖尿病患者的一线治疗选择之一，认为在二甲双胍不耐受或存在使用禁忌等情况下，DPP-4抑制剂可以作为一线的替代治疗药物。在刚刚结束的2017年CDS年会上，贾伟平教授简单介绍了即将发布的《中国2型糖尿病防治指南(2017年版)》(简称2017版指南)的一些内容，在高血糖治疗流程上一个主要变化是把原来的一线、二线、三线药物改为单药、二联和三联治疗，这相当于进一步强调了二甲双胍的重要地位，因为二联和三联治疗均推荐在二甲双胍基础上加用其他药物，而且在单药治疗中，二甲双胍不耐受或存在禁忌时的备选药物给出的是α一糖苷酶抑制剂和胰岛素促泌剂。个人认为，推荐α一糖苷酶抑制剂是考虑到餐后高血糖(尤其是单纯餐后高血糖)在国内很常见，推荐胰岛素促泌剂则是因为其降糖效力和二甲双胍相当，而未推荐DPP-4抑制剂一方面可能是从经济和可获得性角度考虑，另一方面可能是其降糖效力略弱。碰巧在2017年CDS年会上，纪立农教授题为《血糖达标的策略：2型糖尿病起始治疗》的报告中，恰巧也分析了起始单药治疗时，二甲双胍与DPP-4抑制剂的对比情况。2016—2017年发表的比较二甲双胍和西格列汀、阿格列汀、利格列汀的三项中国研究均发现，无论是低剂量还是高剂量(1700或2000毫克/天)的二甲双胍治疗，其降糖疗效都要优于DPP-4抑制剂。因此，纪教授的观点是，对于单药治疗患者，高剂量二甲双胍应作为常规起始治疗。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "快速建议指南推荐DPP-4抑制剂作为2型糖尿病患者的一线治疗选择之一，认为在二甲双胍不耐受或存在使用禁忌等情况下，DPP-4抑制剂可以作为一线的替代治疗药物。在刚刚结束的2017年CDS年会上，贾伟平教授简单介绍了即将发布的《中国2型糖尿病防治指南(2017年版)》(简称2017版指南)的一些内容，在高血糖治疗流程上一个主要变化是把原来的一线、二线、三线药物改为单药、二联和三联治疗，这相当于进一步强调了二甲双胍的重要地位，因为二联和三联治疗均推荐在二甲双胍基础上加用其他药物，而且在单药治疗中，二甲双胍不耐受或存在禁忌时的备选药物给出的是α一糖苷酶抑制剂和胰岛素促泌剂。个人认为，推荐α一糖苷酶抑制剂是考虑到餐后高血糖(尤其是单纯餐后高血糖)在国内很常见，推荐胰岛素促泌剂则是因为其降糖效力和二甲双胍相当，而未推荐DPP-4抑制剂一方面可能是从经济和可获得性角度考虑，另一方面可能是其降糖效力略弱。碰巧在2017年CDS年会上，纪立农教授题为《血糖达标的策略：2型糖尿病起始治疗》的报告中，恰巧也分析了起始单药治疗时，二甲双胍与DPP-4抑制剂的对比情况。2016—2017年发表的比较二甲双胍和西格列汀、阿格列汀、利格列汀的三项中国研究均发现，无论是低剂量还是高剂量(1700或2000毫克/天)的二甲双胍治疗，其降糖疗效都要优于DPP-4抑制剂。",
          "start_idx": 0,
          "end_idx": 577,
          "entities": [
            {
              "entity_id": "T52",
              "entity": "DPP-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 8,
              "end_idx": 16
            },
            {
              "entity_id": "T53",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 38,
              "end_idx": 42
            },
            {
              "entity_id": "T54",
              "entity": "DPP-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 57,
              "end_idx": 65
            },
            {
              "entity_id": "T55",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 203,
              "end_idx": 207
            },
            {
              "entity_id": "T56",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 226,
              "end_idx": 230
            },
            {
              "entity_id": "T57",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 249,
              "end_idx": 253
            },
            {
              "entity_id": "T58",
              "entity": "α一糖苷酶抑制剂",
              "entity_type": "Drug",
              "start_idx": 271,
              "end_idx": 279
            },
            {
              "entity_id": "T59",
              "entity": "胰岛素促泌剂",
              "entity_type": "Drug",
              "start_idx": 280,
              "end_idx": 286
            },
            {
              "entity_id": "T60",
              "entity": "α一糖苷酶抑制剂",
              "entity_type": "Drug",
              "start_idx": 294,
              "end_idx": 302
            },
            {
              "entity_id": "T61",
              "entity": "胰岛素促泌剂",
              "entity_type": "Drug",
              "start_idx": 332,
              "end_idx": 338
            },
            {
              "entity_id": "T62",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 348,
              "end_idx": 352
            },
            {
              "entity_id": "T63",
              "entity": "DPP-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 359,
              "end_idx": 367
            },
            {
              "entity_id": "T64",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 461,
              "end_idx": 465
            },
            {
              "entity_id": "T65",
              "entity": "DPP-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 466,
              "end_idx": 474
            },
            {
              "entity_id": "T66",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 495,
              "end_idx": 499
            },
            {
              "entity_id": "T67",
              "entity": "西格列汀",
              "entity_type": "Drug",
              "start_idx": 500,
              "end_idx": 504
            },
            {
              "entity_id": "T68",
              "entity": "阿格列汀",
              "entity_type": "Drug",
              "start_idx": 505,
              "end_idx": 509
            },
            {
              "entity_id": "T69",
              "entity": "利格列汀",
              "entity_type": "Drug",
              "start_idx": 510,
              "end_idx": 514
            },
            {
              "entity_id": "T70",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 552,
              "end_idx": 556
            },
            {
              "entity_id": "T71",
              "entity": "DPP-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 568,
              "end_idx": 576
            },
            {
              "entity_id": "T73",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 18,
              "end_idx": 23
            },
            {
              "entity_id": "T74",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 115,
              "end_idx": 120
            },
            {
              "entity_id": "T75",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 432,
              "end_idx": 437
            },
            {
              "entity_id": "T76",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 18,
              "end_idx": 20
            },
            {
              "entity_id": "T77",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 115,
              "end_idx": 117
            },
            {
              "entity_id": "T78",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 432,
              "end_idx": 434
            },
            {
              "entity_id": "T79",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 151,
              "end_idx": 154
            },
            {
              "entity_id": "T80",
              "entity": "餐后高血糖",
              "entity_type": "Disease",
              "start_idx": 306,
              "end_idx": 311
            },
            {
              "entity_id": "T81",
              "entity": "餐后高血糖",
              "entity_type": "Disease",
              "start_idx": 317,
              "end_idx": 322
            },
            {
              "entity_id": "T82",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 424,
              "end_idx": 426
            },
            {
              "entity_id": "T83",
              "entity": "达标",
              "entity_type": "Test_Value",
              "start_idx": 426,
              "end_idx": 428
            },
            {
              "entity_id": "T84",
              "entity": "1700或2000毫克/天",
              "entity_type": "Amount",
              "start_idx": 537,
              "end_idx": 550
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R5",
              "head_entity_id": "T52",
              "tail_entity_id": "T73"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R6",
              "head_entity_id": "T64",
              "tail_entity_id": "T75"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R7",
              "head_entity_id": "T65",
              "tail_entity_id": "T75"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R8",
              "head_entity_id": "T84",
              "tail_entity_id": "T70"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R9",
              "head_entity_id": "T76",
              "tail_entity_id": "T73"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R10",
              "head_entity_id": "T77",
              "tail_entity_id": "T74"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R11",
              "head_entity_id": "T78",
              "tail_entity_id": "T75"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R12",
              "head_entity_id": "T82",
              "tail_entity_id": "T75"
            }
          ]
        },
        {
          "sentence_id": "1",
          "sentence": "因此，纪教授的观点是，对于单药治疗患者，高剂量二甲双胍应作为常规起始治疗。",
          "start_idx": 577,
          "end_idx": 614,
          "entities": [
            {
              "entity_id": "T72",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 23,
              "end_idx": 27
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "11",
      "paragraph": "(2)联合用药",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(2)联合用药",
          "start_idx": 0,
          "end_idx": 7,
          "entities": [],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "12",
      "paragraph": "快速建议指南推荐DPP-4抑制剂作为2型糖尿病患者的二线和三线治疗选择之一，指出在当二甲双胍或者其他降糖药物单药治疗后，如糖化血红蛋白水平仍未达标，可联合此类药物。2017版指南也同样将DPP-4抑制剂列为与二甲双胍进行二联或三联治疗的选择之一。在这一点上，两个指南并没有分歧，然而。从最新的国内研究证据来看，在二甲双胍高剂量(2000毫克/天)单药治疗的基础上，加用DPP-4抑制剂只能使糖化血红蛋白进一步下降约0-2%，而减重作用反而更差一些，而在欧美人群中进行的研究中，糖化血红蛋白进一步下降了约0.5%，这是否是降糖药物的又一个中国特色呢(前一个中国特色是α-糖苷酶抑制剂的“西方不亮东方亮”——本刊注)?不过，DPP-4抑制剂可以带来多重获益。我们或许不能单以降低糖化血红蛋白的能力论英雄。这些都还有待更多的研究来论证。毕竟这类药物进入我国临床只有短短几年而已。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "快速建议指南推荐DPP-4抑制剂作为2型糖尿病患者的二线和三线治疗选择之一，指出在当二甲双胍或者其他降糖药物单药治疗后，如糖化血红蛋白水平仍未达标，可联合此类药物。2017版指南也同样将DPP-4抑制剂列为与二甲双胍进行二联或三联治疗的选择之一。在这一点上，两个指南并没有分歧，然而。从最新的国内研究证据来看，在二甲双胍高剂量(2000毫克/天)单药治疗的基础上，加用DPP-4抑制剂只能使糖化血红蛋白进一步下降约0-2%，而减重作用反而更差一些，而在欧美人群中进行的研究中，糖化血红蛋白进一步下降了约0.5%，这是否是降糖药物的又一个中国特色呢(前一个中国特色是α-糖苷酶抑制剂的“西方不亮东方亮”——本刊注)?不过，DPP-4抑制剂可以带来多重获益。",
          "start_idx": 0,
          "end_idx": 327,
          "entities": [
            {
              "entity_id": "T85",
              "entity": "DPP-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 8,
              "end_idx": 16
            },
            {
              "entity_id": "T86",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 42,
              "end_idx": 46
            },
            {
              "entity_id": "T87",
              "entity": "DPP-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 93,
              "end_idx": 101
            },
            {
              "entity_id": "T88",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 104,
              "end_idx": 108
            },
            {
              "entity_id": "T89",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 156,
              "end_idx": 160
            },
            {
              "entity_id": "T90",
              "entity": "DPP-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 184,
              "end_idx": 192
            },
            {
              "entity_id": "T91",
              "entity": "α-糖苷酶抑制剂",
              "entity_type": "Drug",
              "start_idx": 282,
              "end_idx": 290
            },
            {
              "entity_id": "T92",
              "entity": "DPP-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 310,
              "end_idx": 318
            },
            {
              "entity_id": "T93",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 18,
              "end_idx": 23
            },
            {
              "entity_id": "T94",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 18,
              "end_idx": 20
            },
            {
              "entity_id": "T95",
              "entity": "糖化血红蛋白",
              "entity_type": "Test_items",
              "start_idx": 61,
              "end_idx": 67
            },
            {
              "entity_id": "T96",
              "entity": "糖化血红蛋白",
              "entity_type": "Test_items",
              "start_idx": 195,
              "end_idx": 201
            },
            {
              "entity_id": "T97",
              "entity": "糖化血红蛋白",
              "entity_type": "Test_items",
              "start_idx": 238,
              "end_idx": 244
            },
            {
              "entity_id": "T98",
              "entity": "2000毫克/天",
              "entity_type": "Amount",
              "start_idx": 164,
              "end_idx": 172
            },
            {
              "entity_id": "T99",
              "entity": "未达标",
              "entity_type": "Test_Value",
              "start_idx": 70,
              "end_idx": 73
            },
            {
              "entity_id": "T100",
              "entity": "下降约0-2%",
              "entity_type": "Test_Value",
              "start_idx": 204,
              "end_idx": 211
            },
            {
              "entity_id": "T101",
              "entity": "下降了约0.5%",
              "entity_type": "Test_Value",
              "start_idx": 247,
              "end_idx": 255
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R13",
              "head_entity_id": "T85",
              "tail_entity_id": "T93"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R14",
              "head_entity_id": "T86",
              "tail_entity_id": "T93"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R15",
              "head_entity_id": "T98",
              "tail_entity_id": "T89"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R16",
              "head_entity_id": "T94",
              "tail_entity_id": "T93"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R17",
              "head_entity_id": "T95",
              "tail_entity_id": "T93"
            }
          ]
        },
        {
          "sentence_id": "1",
          "sentence": "我们或许不能单以降低糖化血红蛋白的能力论英雄。",
          "start_idx": 327,
          "end_idx": 350,
          "entities": [
            {
              "entity_id": "T102",
              "entity": "糖化血红蛋白",
              "entity_type": "Test_items",
              "start_idx": 10,
              "end_idx": 16
            }
          ],
          "relations": []
        },
        {
          "sentence_id": "2",
          "sentence": "这些都还有待更多的研究来论证。",
          "start_idx": 350,
          "end_idx": 365,
          "entities": [],
          "relations": []
        },
        {
          "sentence_id": "3",
          "sentence": "毕竟这类药物进入我国临床只有短短几年而已。",
          "start_idx": 365,
          "end_idx": 386,
          "entities": [],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "13",
      "paragraph": "(3)用法用量",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(3)用法用量",
          "start_idx": 0,
          "end_idx": 7,
          "entities": [],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "14",
      "paragraph": "快速建议指南推荐DPP-4抑制剂的剂量为说明中规定的常规使用剂量。临床应用共识则给出了更详细的肝肾功能不全患者的用法用量：",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "快速建议指南推荐DPP-4抑制剂的剂量为说明中规定的常规使用剂量。临床应用共识则给出了更详细的肝肾功能不全患者的用法用量：",
          "start_idx": 0,
          "end_idx": 61,
          "entities": [
            {
              "entity_id": "T103",
              "entity": "DPP-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 8,
              "end_idx": 16
            },
            {
              "entity_id": "T104",
              "entity": "肝肾功能不全",
              "entity_type": "Disease",
              "start_idx": 47,
              "end_idx": 53
            },
            {
              "entity_id": "T105",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 47,
              "end_idx": 48
            },
            {
              "entity_id": "T106",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 48,
              "end_idx": 49
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R18",
              "head_entity_id": "T105",
              "tail_entity_id": "T104"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R19",
              "head_entity_id": "T106",
              "tail_entity_id": "T104"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "17",
      "paragraph": "特殊情况",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "特殊情况",
          "start_idx": 0,
          "end_idx": 4,
          "entities": [],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "18",
      "paragraph": "(1)与胰岛素联用",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(1)与胰岛素联用",
          "start_idx": 0,
          "end_idx": 9,
          "entities": [
            {
              "entity_id": "T107",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 4,
              "end_idx": 7
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "20",
      "paragraph": "(2)老年患者",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(2)老年患者",
          "start_idx": 0,
          "end_idx": 7,
          "entities": [],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "21",
      "paragraph": "快速建议指南推荐DPP-4抑制剂用于65岁以上的2型糖尿病患者的降糖治疗。其理由是，老年患者常常合并多种并发疾病，而DPP-4抑制剂具有良好的血糖控制效果和安全性，同时也指出，推荐使用常规剂量进行治疗，但如患者伴有肝或肾功能不全，则需要根据说明书进行剂量调整。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "快速建议指南推荐DPP-4抑制剂用于65岁以上的2型糖尿病患者的降糖治疗。其理由是，老年患者常常合并多种并发疾病，而DPP-4抑制剂具有良好的血糖控制效果和安全性，同时也指出，推荐使用常规剂量进行治疗，但如患者伴有肝或肾功能不全，则需要根据说明书进行剂量调整。",
          "start_idx": 0,
          "end_idx": 130,
          "entities": [
            {
              "entity_id": "T108",
              "entity": "DPP-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 8,
              "end_idx": 16
            },
            {
              "entity_id": "T109",
              "entity": "DPP-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 58,
              "end_idx": 66
            },
            {
              "entity_id": "T110",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 24,
              "end_idx": 29
            },
            {
              "entity_id": "T111",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 24,
              "end_idx": 26
            },
            {
              "entity_id": "T112",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 71,
              "end_idx": 73
            },
            {
              "entity_id": "T113",
              "entity": "肝或肾功能不全",
              "entity_type": "Disease",
              "start_idx": 107,
              "end_idx": 114
            },
            {
              "entity_id": "T114",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 107,
              "end_idx": 108
            },
            {
              "entity_id": "T115",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 109,
              "end_idx": 110
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R20",
              "head_entity_id": "T111",
              "tail_entity_id": "T110"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R21",
              "head_entity_id": "T112",
              "tail_entity_id": "T110"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R22",
              "head_entity_id": "T114",
              "tail_entity_id": "T113"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R23",
              "head_entity_id": "T115",
              "tail_entity_id": "T113"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "22",
      "paragraph": "(3)超重/肥胖患者",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(3)超重/肥胖患者",
          "start_idx": 0,
          "end_idx": 10,
          "entities": [
            {
              "entity_id": "T116",
              "entity": "超重",
              "entity_type": "Disease",
              "start_idx": 3,
              "end_idx": 5
            },
            {
              "entity_id": "T117",
              "entity": "肥胖",
              "entity_type": "Disease",
              "start_idx": 6,
              "end_idx": 8
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "23",
      "paragraph": "快速建议指南认为DPP-4抑制剂可用于超重/肥胖2型糖尿病患者的降糖治疗，理由是DPP-4抑制剂并不影响患者的体重。然而，如前所述，最新研究显示在二甲双胍治疗基础上加上DPP-4抑制剂，患者的体重减轻幅度反而变小了，其原因还需要进一步的研究来明确。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "快速建议指南认为DPP-4抑制剂可用于超重/肥胖2型糖尿病患者的降糖治疗，理由是DPP-4抑制剂并不影响患者的体重。",
          "start_idx": 0,
          "end_idx": 58,
          "entities": [
            {
              "entity_id": "T118",
              "entity": "DPP-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 8,
              "end_idx": 16
            },
            {
              "entity_id": "T119",
              "entity": "DPP-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 40,
              "end_idx": 48
            },
            {
              "entity_id": "T122",
              "entity": "超重",
              "entity_type": "Disease",
              "start_idx": 19,
              "end_idx": 21
            },
            {
              "entity_id": "T123",
              "entity": "肥胖",
              "entity_type": "Disease",
              "start_idx": 22,
              "end_idx": 24
            },
            {
              "entity_id": "T124",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 24,
              "end_idx": 29
            },
            {
              "entity_id": "T125",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 24,
              "end_idx": 26
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R24",
              "head_entity_id": "T118",
              "tail_entity_id": "T122"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R25",
              "head_entity_id": "T118",
              "tail_entity_id": "T123"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R26",
              "head_entity_id": "T118",
              "tail_entity_id": "T124"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R27",
              "head_entity_id": "T125",
              "tail_entity_id": "T124"
            }
          ]
        },
        {
          "sentence_id": "1",
          "sentence": "然而，如前所述，最新研究显示在二甲双胍治疗基础上加上DPP-4抑制剂，患者的体重减轻幅度反而变小了，其原因还需要进一步的研究来明确。",
          "start_idx": 58,
          "end_idx": 124,
          "entities": [
            {
              "entity_id": "T120",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 15,
              "end_idx": 19
            },
            {
              "entity_id": "T121",
              "entity": "DPP-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 26,
              "end_idx": 34
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "24",
      "paragraph": "(4)伴心血管疾病或心血管风险高的患者",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(4)伴心血管疾病或心血管风险高的患者",
          "start_idx": 0,
          "end_idx": 19,
          "entities": [
            {
              "entity_id": "T126",
              "entity": "心血管疾病",
              "entity_type": "Disease",
              "start_idx": 4,
              "end_idx": 9
            },
            {
              "entity_id": "T127",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 4,
              "end_idx": 7
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R28",
              "head_entity_id": "T127",
              "tail_entity_id": "T126"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "25",
      "paragraph": "快速建议指南基于证据总结和专家意见，认为DPP-4抑制剂可用于伴有心血管疾病或心血管事件风险的2型糖尿病患者的降糖治疗。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "快速建议指南基于证据总结和专家意见，认为DPP-4抑制剂可用于伴有心血管疾病或心血管事件风险的2型糖尿病患者的降糖治疗。",
          "start_idx": 0,
          "end_idx": 60,
          "entities": [
            {
              "entity_id": "T128",
              "entity": "DPP-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 20,
              "end_idx": 28
            },
            {
              "entity_id": "T129",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 47,
              "end_idx": 52
            },
            {
              "entity_id": "T130",
              "entity": "心血管疾病",
              "entity_type": "Disease",
              "start_idx": 33,
              "end_idx": 38
            },
            {
              "entity_id": "T131",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 33,
              "end_idx": 36
            },
            {
              "entity_id": "T132",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 47,
              "end_idx": 49
            },
            {
              "entity_id": "T133",
              "entity": "心血管事件",
              "entity_type": "Disease",
              "start_idx": 39,
              "end_idx": 44
            },
            {
              "entity_id": "T134",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 39,
              "end_idx": 42
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R29",
              "head_entity_id": "T128",
              "tail_entity_id": "T130"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R30",
              "head_entity_id": "T128",
              "tail_entity_id": "T129"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R31",
              "head_entity_id": "T132",
              "tail_entity_id": "T129"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R32",
              "head_entity_id": "T131",
              "tail_entity_id": "T130"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R33",
              "head_entity_id": "T134",
              "tail_entity_id": "T133"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "26",
      "paragraph": "(5)复方制剂",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(5)复方制剂",
          "start_idx": 0,
          "end_idx": 7,
          "entities": [],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "27",
      "paragraph": "快速建议指南推荐复方制剂(DPP-4抑制剂和二甲双胍)用于2型糖尿病患者的起始降糖治疗，指出对于糖化血红蛋白>7.5%的首次治疗患者，推荐使用复方制剂(DPP-4抑制剂和二甲双胍)进行起始治疗。不过就像前面提到的，这种用法可能还有待商榷。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "快速建议指南推荐复方制剂(DPP-4抑制剂和二甲双胍)用于2型糖尿病患者的起始降糖治疗，指出对于糖化血红蛋白>7.5%的首次治疗患者，推荐使用复方制剂(DPP-4抑制剂和二甲双胍)进行起始治疗。",
          "start_idx": 0,
          "end_idx": 97,
          "entities": [
            {
              "entity_id": "T135",
              "entity": "DPP-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 13,
              "end_idx": 21
            },
            {
              "entity_id": "T136",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 22,
              "end_idx": 26
            },
            {
              "entity_id": "T137",
              "entity": "DPP-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 76,
              "end_idx": 84
            },
            {
              "entity_id": "T138",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 85,
              "end_idx": 89
            },
            {
              "entity_id": "T139",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 29,
              "end_idx": 34
            },
            {
              "entity_id": "T140",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 29,
              "end_idx": 31
            },
            {
              "entity_id": "T141",
              "entity": "糖化血红蛋白",
              "entity_type": "Test_items",
              "start_idx": 48,
              "end_idx": 54
            },
            {
              "entity_id": "T142",
              "entity": ">7.5%",
              "entity_type": "Test_Value",
              "start_idx": 54,
              "end_idx": 59
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R34",
              "head_entity_id": "T135",
              "tail_entity_id": "T139"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R35",
              "head_entity_id": "T136",
              "tail_entity_id": "T139"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R36",
              "head_entity_id": "T141",
              "tail_entity_id": "T139"
            }
          ]
        },
        {
          "sentence_id": "1",
          "sentence": "不过就像前面提到的，这种用法可能还有待商榷。",
          "start_idx": 97,
          "end_idx": 119,
          "entities": [],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "28",
      "paragraph": "(6)超敏反应",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(6)超敏反应",
          "start_idx": 0,
          "end_idx": 7,
          "entities": [],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "29",
      "paragraph": "临床应用共识指出西格列汀在上市后发现有严重超敏反应，包括过敏反应、血管性水肿和剥脱性皮肤损害，如怀疑发生超敏反应时应停用；维格列汀尽管在临床中未观察到皮肤损伤发生率升高，但在合并糖尿病皮肤并发症的患者中经验有限，建议观察皮肤病变，如水疱、皮疹或溃疡等情况；阿格列汀在上市后发现严重皮肤不良反应，如怀疑发生严重过敏反应时应停用；沙格列汀上市后有报告严重超敏反应(包括速发过敏反应和血管性水肿)，怀疑时应停用；利格列汀在临床研究中也报告有高敏反应，如荨麻疹、血管性水肿、局部皮肤剥脱或支气管高敏反应。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "临床应用共识指出西格列汀在上市后发现有严重超敏反应，包括过敏反应、血管性水肿和剥脱性皮肤损害，如怀疑发生超敏反应时应停用；维格列汀尽管在临床中未观察到皮肤损伤发生率升高，但在合并糖尿病皮肤并发症的患者中经验有限，建议观察皮肤病变，如水疱、皮疹或溃疡等情况；阿格列汀在上市后发现严重皮肤不良反应，如怀疑发生严重过敏反应时应停用；沙格列汀上市后有报告严重超敏反应(包括速发过敏反应和血管性水肿)，怀疑时应停用；利格列汀在临床研究中也报告有高敏反应，如荨麻疹、血管性水肿、局部皮肤剥脱或支气管高敏反应。",
          "start_idx": 0,
          "end_idx": 248,
          "entities": [
            {
              "entity_id": "T143",
              "entity": "西格列汀",
              "entity_type": "Drug",
              "start_idx": 8,
              "end_idx": 12
            },
            {
              "entity_id": "T144",
              "entity": "维格列汀",
              "entity_type": "Drug",
              "start_idx": 61,
              "end_idx": 65
            },
            {
              "entity_id": "T145",
              "entity": "阿格列汀",
              "entity_type": "Drug",
              "start_idx": 128,
              "end_idx": 132
            },
            {
              "entity_id": "T146",
              "entity": "沙格列汀",
              "entity_type": "Drug",
              "start_idx": 163,
              "end_idx": 167
            },
            {
              "entity_id": "T147",
              "entity": "利格列汀",
              "entity_type": "Drug",
              "start_idx": 203,
              "end_idx": 207
            },
            {
              "entity_id": "T148",
              "entity": "糖尿病皮肤并发症",
              "entity_type": "Disease",
              "start_idx": 89,
              "end_idx": 97
            },
            {
              "entity_id": "T149",
              "entity": "超敏反应",
              "entity_type": "ADE",
              "start_idx": 21,
              "end_idx": 25
            },
            {
              "entity_id": "T150",
              "entity": "过敏反应",
              "entity_type": "ADE",
              "start_idx": 28,
              "end_idx": 32
            },
            {
              "entity_id": "T151",
              "entity": "血管性水肿",
              "entity_type": "ADE",
              "start_idx": 33,
              "end_idx": 38
            },
            {
              "entity_id": "T152",
              "entity": "剥脱性皮肤损害",
              "entity_type": "ADE",
              "start_idx": 39,
              "end_idx": 46
            },
            {
              "entity_id": "T153",
              "entity": "超敏反应",
              "entity_type": "ADE",
              "start_idx": 52,
              "end_idx": 56
            },
            {
              "entity_id": "T154",
              "entity": "皮肤损伤发生率升高",
              "entity_type": "ADE",
              "start_idx": 75,
              "end_idx": 84
            },
            {
              "entity_id": "T155",
              "entity": "皮肤病变",
              "entity_type": "ADE",
              "start_idx": 110,
              "end_idx": 114
            },
            {
              "entity_id": "T156",
              "entity": "水疱",
              "entity_type": "ADE",
              "start_idx": 116,
              "end_idx": 118
            },
            {
              "entity_id": "T157",
              "entity": "皮疹",
              "entity_type": "ADE",
              "start_idx": 119,
              "end_idx": 121
            },
            {
              "entity_id": "T158",
              "entity": "溃疡",
              "entity_type": "ADE",
              "start_idx": 122,
              "end_idx": 124
            },
            {
              "entity_id": "T159",
              "entity": "皮肤不良反应",
              "entity_type": "ADE",
              "start_idx": 140,
              "end_idx": 146
            },
            {
              "entity_id": "T160",
              "entity": "过敏反应",
              "entity_type": "ADE",
              "start_idx": 154,
              "end_idx": 158
            },
            {
              "entity_id": "T161",
              "entity": "超敏反应",
              "entity_type": "ADE",
              "start_idx": 175,
              "end_idx": 179
            },
            {
              "entity_id": "T162",
              "entity": "速发过敏反应",
              "entity_type": "ADE",
              "start_idx": 182,
              "end_idx": 188
            },
            {
              "entity_id": "T163",
              "entity": "血管性水肿",
              "entity_type": "ADE",
              "start_idx": 189,
              "end_idx": 194
            },
            {
              "entity_id": "T164",
              "entity": "高敏反应",
              "entity_type": "ADE",
              "start_idx": 217,
              "end_idx": 221
            },
            {
              "entity_id": "T165",
              "entity": "荨麻疹",
              "entity_type": "ADE",
              "start_idx": 223,
              "end_idx": 226
            },
            {
              "entity_id": "T166",
              "entity": "血管性水肿",
              "entity_type": "ADE",
              "start_idx": 227,
              "end_idx": 232
            },
            {
              "entity_id": "T167",
              "entity": "局部皮肤剥脱",
              "entity_type": "ADE",
              "start_idx": 233,
              "end_idx": 239
            },
            {
              "entity_id": "T168",
              "entity": "支气管高敏反应",
              "entity_type": "ADE",
              "start_idx": 240,
              "end_idx": 247
            },
            {
              "entity_id": "T169",
              "entity": "严重",
              "entity_type": "Level",
              "start_idx": 19,
              "end_idx": 21
            },
            {
              "entity_id": "T170",
              "entity": "严重",
              "entity_type": "Level",
              "start_idx": 138,
              "end_idx": 140
            },
            {
              "entity_id": "T171",
              "entity": "严重",
              "entity_type": "Level",
              "start_idx": 152,
              "end_idx": 154
            },
            {
              "entity_id": "T172",
              "entity": "严重",
              "entity_type": "Level",
              "start_idx": 173,
              "end_idx": 175
            },
            {
              "entity_id": "T173",
              "entity": "皮肤",
              "entity_type": "Anatomy",
              "start_idx": 92,
              "end_idx": 94
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R37",
              "head_entity_id": "T149",
              "tail_entity_id": "T143"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R38",
              "head_entity_id": "T150",
              "tail_entity_id": "T143"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R39",
              "head_entity_id": "T151",
              "tail_entity_id": "T143"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R40",
              "head_entity_id": "T152",
              "tail_entity_id": "T143"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R41",
              "head_entity_id": "T153",
              "tail_entity_id": "T143"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R42",
              "head_entity_id": "T159",
              "tail_entity_id": "T145"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R43",
              "head_entity_id": "T160",
              "tail_entity_id": "T145"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R44",
              "head_entity_id": "T161",
              "tail_entity_id": "T146"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R45",
              "head_entity_id": "T162",
              "tail_entity_id": "T146"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R46",
              "head_entity_id": "T163",
              "tail_entity_id": "T146"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R47",
              "head_entity_id": "T165",
              "tail_entity_id": "T147"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R48",
              "head_entity_id": "T164",
              "tail_entity_id": "T147"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R49",
              "head_entity_id": "T166",
              "tail_entity_id": "T147"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R50",
              "head_entity_id": "T167",
              "tail_entity_id": "T147"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R51",
              "head_entity_id": "T168",
              "tail_entity_id": "T147"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R52",
              "head_entity_id": "T173",
              "tail_entity_id": "T148"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "30",
      "paragraph": "(7)药物相互作用",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(7)药物相互作用",
          "start_idx": 0,
          "end_idx": 9,
          "entities": [],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "31",
      "paragraph": "西格列汀与磺脲类药物合用时低血糖风险增加，需适当减少磺脲类剂量；利格列汀与胰岛素、磺脲类合用时低血糖风险增加，需适当减少胰岛素和磺脲类剂量；沙格列汀与酮康唑、阿扎那韦、克拉霉素、茚地那韦、伊曲康唑、奈法唑酮、奈非那韦、利托那韦、沙奎那韦和泰利霉素等合用时，应将剂量限制为2.5毫克/天。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "西格列汀与磺脲类药物合用时低血糖风险增加，需适当减少磺脲类剂量；利格列汀与胰岛素、磺脲类合用时低血糖风险增加，需适当减少胰岛素和磺脲类剂量；沙格列汀与酮康唑、阿扎那韦、克拉霉素、茚地那韦、伊曲康唑、奈法唑酮、奈非那韦、利托那韦、沙奎那韦和泰利霉素等合用时，应将剂量限制为2.5毫克/天。",
          "start_idx": 0,
          "end_idx": 143,
          "entities": [
            {
              "entity_id": "T174",
              "entity": "西格列汀",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 4
            },
            {
              "entity_id": "T175",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 5,
              "end_idx": 10
            },
            {
              "entity_id": "T176",
              "entity": "磺脲类",
              "entity_type": "Drug",
              "start_idx": 26,
              "end_idx": 29
            },
            {
              "entity_id": "T177",
              "entity": "利格列汀",
              "entity_type": "Drug",
              "start_idx": 32,
              "end_idx": 36
            },
            {
              "entity_id": "T178",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 37,
              "end_idx": 40
            },
            {
              "entity_id": "T179",
              "entity": "磺脲类",
              "entity_type": "Drug",
              "start_idx": 41,
              "end_idx": 44
            },
            {
              "entity_id": "T180",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 60,
              "end_idx": 63
            },
            {
              "entity_id": "T181",
              "entity": "磺脲类",
              "entity_type": "Drug",
              "start_idx": 64,
              "end_idx": 67
            },
            {
              "entity_id": "T182",
              "entity": "沙格列汀",
              "entity_type": "Drug",
              "start_idx": 70,
              "end_idx": 74
            },
            {
              "entity_id": "T183",
              "entity": "酮康唑",
              "entity_type": "Drug",
              "start_idx": 75,
              "end_idx": 78
            },
            {
              "entity_id": "T184",
              "entity": "阿扎那韦",
              "entity_type": "Drug",
              "start_idx": 79,
              "end_idx": 83
            },
            {
              "entity_id": "T185",
              "entity": "克拉霉素",
              "entity_type": "Drug",
              "start_idx": 84,
              "end_idx": 88
            },
            {
              "entity_id": "T186",
              "entity": "茚地那韦",
              "entity_type": "Drug",
              "start_idx": 89,
              "end_idx": 93
            },
            {
              "entity_id": "T187",
              "entity": "伊曲康唑",
              "entity_type": "Drug",
              "start_idx": 94,
              "end_idx": 98
            },
            {
              "entity_id": "T188",
              "entity": "奈法唑酮",
              "entity_type": "Drug",
              "start_idx": 99,
              "end_idx": 103
            },
            {
              "entity_id": "T189",
              "entity": "奈非那韦",
              "entity_type": "Drug",
              "start_idx": 104,
              "end_idx": 108
            },
            {
              "entity_id": "T190",
              "entity": "利托那韦",
              "entity_type": "Drug",
              "start_idx": 109,
              "end_idx": 113
            },
            {
              "entity_id": "T191",
              "entity": "沙奎那韦",
              "entity_type": "Drug",
              "start_idx": 114,
              "end_idx": 118
            },
            {
              "entity_id": "T192",
              "entity": "泰利霉素",
              "entity_type": "Drug",
              "start_idx": 119,
              "end_idx": 123
            },
            {
              "entity_id": "T193",
              "entity": "低血糖风险增加",
              "entity_type": "ADE",
              "start_idx": 13,
              "end_idx": 20
            },
            {
              "entity_id": "T194",
              "entity": "低血糖风险增加",
              "entity_type": "ADE",
              "start_idx": 47,
              "end_idx": 54
            },
            {
              "entity_id": "T195",
              "entity": "2.5毫克/天",
              "entity_type": "Amount",
              "start_idx": 135,
              "end_idx": 142
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R53",
              "head_entity_id": "T193",
              "tail_entity_id": "T174"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R54",
              "head_entity_id": "T193",
              "tail_entity_id": "T175"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R55",
              "head_entity_id": "T194",
              "tail_entity_id": "T177"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R56",
              "head_entity_id": "T194",
              "tail_entity_id": "T178"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R57",
              "head_entity_id": "T194",
              "tail_entity_id": "T179"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R58",
              "head_entity_id": "T195",
              "tail_entity_id": "T182"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "32",
      "paragraph": "GLP一1受体激动剂：(《基于胰高血糖素样肽1降糖药物的临床应用共识》/《基于肠促胰素的药物治疗临床应用的快速建议指南》)",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "GLP一1受体激动剂：(《基于胰高血糖素样肽1降糖药物的临床应用共识》/《基于肠促胰素的药物治疗临床应用的快速建议指南》)",
          "start_idx": 0,
          "end_idx": 61,
          "entities": [
            {
              "entity_id": "T196",
              "entity": "GLP一1受体激动剂",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 10
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "33",
      "paragraph": "由于GLP一1受体广泛分布在胰岛细胞、胃肠、肺、脑、肾脏、下丘脑、心血管系统、肝脏、脂肪组织和骨骼肌，所以GLP-1除了能促进胰岛素分泌和抑制胰高血糖素分泌之外，还具有延缓胃排空和肠蠕动、抑制食欲、增加饱腹感、降压、降脂、保护肾脏等多方面的作用。也正因为如此，GLP-1受体激动剂类药物近年来备受关注和推崇，需要注射给药这一原本的短板，也随着每周一次的超长效制剂出现而得到弥补，每半月或每月给药一次的制剂也正在研发中，这类药物目前来看简直完美。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "由于GLP一1受体广泛分布在胰岛细胞、胃肠、肺、脑、肾脏、下丘脑、心血管系统、肝脏、脂肪组织和骨骼肌，所以GLP-1除了能促进胰岛素分泌和抑制胰高血糖素分泌之外，还具有延缓胃排空和肠蠕动、抑制食欲、增加饱腹感、降压、降脂、保护肾脏等多方面的作用。",
          "start_idx": 0,
          "end_idx": 123,
          "entities": [],
          "relations": []
        },
        {
          "sentence_id": "1",
          "sentence": "也正因为如此，GLP-1受体激动剂类药物近年来备受关注和推崇，需要注射给药这一原本的短板，也随着每周一次的超长效制剂出现而得到弥补，每半月或每月给药一次的制剂也正在研发中，这类药物目前来看简直完美。",
          "start_idx": 123,
          "end_idx": 222,
          "entities": [
            {
              "entity_id": "T197",
              "entity": "GLP-1受体激动剂类药物",
              "entity_type": "Drug",
              "start_idx": 7,
              "end_idx": 20
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "34",
      "paragraph": "适用人群",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "适用人群",
          "start_idx": 0,
          "end_idx": 4,
          "entities": [],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "35",
      "paragraph": "临床应用共识指出，GLP-1受体激动剂适用于成人2型糖尿病患者，其中艾塞那肽目前国内适用于单用二甲双胍、磺脲类，以及二甲双胍合用磺脲类，而血糖仍控制不佳的患者，而在国外，艾塞那肽还可与噻唑烷二酮类、二甲双胍合用磺脲类、二甲双胍合用噻唑烷二酮类以及基础胰岛素联合使用等；利拉鲁肽在国内适用于单用二甲双胍或磺脲类药物最大可耐受剂量治疗后血糖仍控制不佳的患者，与二甲双胍或磺脲类药物联合应用，而在国外，利拉鲁肽在此应用基础上还有单药使用，与二甲双胍+磺脲类或与二甲双胍+噻唑烷二酮类或与胰岛素联合应用的适应证等。2017版指南同样将GLP-1受体激动剂列为可与二甲双胍进行二联或三联治疗的注射类药物之一。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "临床应用共识指出，GLP-1受体激动剂适用于成人2型糖尿病患者，其中艾塞那肽目前国内适用于单用二甲双胍、磺脲类，以及二甲双胍合用磺脲类，而血糖仍控制不佳的患者，而在国外，艾塞那肽还可与噻唑烷二酮类、二甲双胍合用磺脲类、二甲双胍合用噻唑烷二酮类以及基础胰岛素联合使用等；利拉鲁肽在国内适用于单用二甲双胍或磺脲类药物最大可耐受剂量治疗后血糖仍控制不佳的患者，与二甲双胍或磺脲类药物联合应用，而在国外，利拉鲁肽在此应用基础上还有单药使用，与二甲双胍+磺脲类或与二甲双胍+噻唑烷二酮类或与胰岛素联合应用的适应证等。",
          "start_idx": 0,
          "end_idx": 253,
          "entities": [
            {
              "entity_id": "T198",
              "entity": "GLP-1受体激动剂",
              "entity_type": "Drug",
              "start_idx": 9,
              "end_idx": 19
            },
            {
              "entity_id": "T199",
              "entity": "艾塞那肽",
              "entity_type": "Drug",
              "start_idx": 34,
              "end_idx": 38
            },
            {
              "entity_id": "T200",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 47,
              "end_idx": 51
            },
            {
              "entity_id": "T201",
              "entity": "磺脲类",
              "entity_type": "Drug",
              "start_idx": 52,
              "end_idx": 55
            },
            {
              "entity_id": "T202",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 58,
              "end_idx": 62
            },
            {
              "entity_id": "T203",
              "entity": "磺脲类",
              "entity_type": "Drug",
              "start_idx": 64,
              "end_idx": 67
            },
            {
              "entity_id": "T204",
              "entity": "艾塞那肽",
              "entity_type": "Drug",
              "start_idx": 85,
              "end_idx": 89
            },
            {
              "entity_id": "T205",
              "entity": "噻唑烷二酮类",
              "entity_type": "Drug",
              "start_idx": 92,
              "end_idx": 98
            },
            {
              "entity_id": "T206",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 99,
              "end_idx": 103
            },
            {
              "entity_id": "T207",
              "entity": "磺脲类",
              "entity_type": "Drug",
              "start_idx": 105,
              "end_idx": 108
            },
            {
              "entity_id": "T208",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 109,
              "end_idx": 113
            },
            {
              "entity_id": "T209",
              "entity": "噻唑烷二酮类",
              "entity_type": "Drug",
              "start_idx": 115,
              "end_idx": 121
            },
            {
              "entity_id": "T210",
              "entity": "基础胰岛素",
              "entity_type": "Drug",
              "start_idx": 123,
              "end_idx": 128
            },
            {
              "entity_id": "T211",
              "entity": "利拉鲁肽",
              "entity_type": "Drug",
              "start_idx": 134,
              "end_idx": 138
            },
            {
              "entity_id": "T212",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 146,
              "end_idx": 150
            },
            {
              "entity_id": "T213",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 151,
              "end_idx": 156
            },
            {
              "entity_id": "T214",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 178,
              "end_idx": 182
            },
            {
              "entity_id": "T215",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 183,
              "end_idx": 188
            },
            {
              "entity_id": "T216",
              "entity": "利拉鲁肽",
              "entity_type": "Drug",
              "start_idx": 198,
              "end_idx": 202
            },
            {
              "entity_id": "T217",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 217,
              "end_idx": 221
            },
            {
              "entity_id": "T218",
              "entity": "磺脲类",
              "entity_type": "Drug",
              "start_idx": 222,
              "end_idx": 225
            },
            {
              "entity_id": "T219",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 227,
              "end_idx": 231
            },
            {
              "entity_id": "T220",
              "entity": "噻唑烷二酮类",
              "entity_type": "Drug",
              "start_idx": 232,
              "end_idx": 238
            },
            {
              "entity_id": "T221",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 240,
              "end_idx": 243
            },
            {
              "entity_id": "T224",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 24,
              "end_idx": 29
            },
            {
              "entity_id": "T225",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 24,
              "end_idx": 26
            },
            {
              "entity_id": "T226",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 69,
              "end_idx": 71
            },
            {
              "entity_id": "T227",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 166,
              "end_idx": 168
            },
            {
              "entity_id": "T228",
              "entity": "控制不佳",
              "entity_type": "Test_Value",
              "start_idx": 72,
              "end_idx": 76
            },
            {
              "entity_id": "T229",
              "entity": "控制不佳",
              "entity_type": "Test_Value",
              "start_idx": 169,
              "end_idx": 173
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R59",
              "head_entity_id": "T225",
              "tail_entity_id": "T224"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R60",
              "head_entity_id": "T226",
              "tail_entity_id": "T224"
            }
          ]
        },
        {
          "sentence_id": "1",
          "sentence": "2017版指南同样将GLP-1受体激动剂列为可与二甲双胍进行二联或三联治疗的注射类药物之一。",
          "start_idx": 253,
          "end_idx": 299,
          "entities": [
            {
              "entity_id": "T222",
              "entity": "GLP-1受体激动剂",
              "entity_type": "Drug",
              "start_idx": 10,
              "end_idx": 20
            },
            {
              "entity_id": "T223",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 24,
              "end_idx": 28
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "36",
      "paragraph": "临床用法",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "临床用法",
          "start_idx": 0,
          "end_idx": 4,
          "entities": [],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "37",
      "paragraph": "临床应用共识推荐参考药品说明书使用。目前，两种GLP-1受体激动剂不仅价格昂贵，而且尚未被纳入医保，因此尽管能够带来多重获益，但临床上仍主要被用于其他降糖药物无法有效控糖的“顽固”患者和经济条件好的患者。我们也期待着这类药物尽快被纳入医保，让更多患者从中获益。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "临床应用共识推荐参考药品说明书使用。",
          "start_idx": 0,
          "end_idx": 18,
          "entities": [],
          "relations": []
        },
        {
          "sentence_id": "1",
          "sentence": "目前，两种GLP-1受体激动剂不仅价格昂贵，而且尚未被纳入医保，因此尽管能够带来多重获益，但临床上仍主要被用于其他降糖药物无法有效控糖的“顽固”患者和经济条件好的患者。",
          "start_idx": 18,
          "end_idx": 102,
          "entities": [
            {
              "entity_id": "T230",
              "entity": "GLP-1受体激动剂",
              "entity_type": "Drug",
              "start_idx": 5,
              "end_idx": 15
            }
          ],
          "relations": []
        },
        {
          "sentence_id": "2",
          "sentence": "我们也期待着这类药物尽快被纳入医保，让更多患者从中获益。",
          "start_idx": 102,
          "end_idx": 130,
          "entities": [],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "38",
      "paragraph": "艾塞那肽和利拉鲁肽使用中有少数急性胰腺炎病例报道，因此临床应用共识建议医生应当告知患者急性胰腺炎的特征性症状，如怀疑发生了胰腺炎。应该立即停用。此外，GLP-1受体激动剂与磺脲类药物合用时低血糖发生率升高，建议适当减少磺脲类药物剂量以减少低血糖风险，当联合使用GLP-1受体激动剂与磺脲类药物时，医生应告知患者在驾驶或操作机械时采取必要措施以防止发生低血糖。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "艾塞那肽和利拉鲁肽使用中有少数急性胰腺炎病例报道，因此临床应用共识建议医生应当告知患者急性胰腺炎的特征性症状，如怀疑发生了胰腺炎。应该立即停用。此外，GLP-1受体激动剂与磺脲类药物合用时低血糖发生率升高，建议适当减少磺脲类药物剂量以减少低血糖风险，当联合使用GLP-1受体激动剂与磺脲类药物时，医生应告知患者在驾驶或操作机械时采取必要措施以防止发生低血糖。",
          "start_idx": 0,
          "end_idx": 179,
          "entities": [
            {
              "entity_id": "T231",
              "entity": "艾塞那肽",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 4
            },
            {
              "entity_id": "T232",
              "entity": "利拉鲁肽",
              "entity_type": "Drug",
              "start_idx": 5,
              "end_idx": 9
            },
            {
              "entity_id": "T233",
              "entity": "GLP-1受体激动剂",
              "entity_type": "Drug",
              "start_idx": 75,
              "end_idx": 85
            },
            {
              "entity_id": "T234",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 86,
              "end_idx": 91
            },
            {
              "entity_id": "T235",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 109,
              "end_idx": 114
            },
            {
              "entity_id": "T236",
              "entity": "GLP-1受体激动剂",
              "entity_type": "Drug",
              "start_idx": 130,
              "end_idx": 140
            },
            {
              "entity_id": "T237",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 141,
              "end_idx": 146
            },
            {
              "entity_id": "T238",
              "entity": "急性胰腺炎",
              "entity_type": "Disease",
              "start_idx": 15,
              "end_idx": 20
            },
            {
              "entity_id": "T239",
              "entity": "急性胰腺炎",
              "entity_type": "Disease",
              "start_idx": 43,
              "end_idx": 48
            },
            {
              "entity_id": "T240",
              "entity": "胰腺炎",
              "entity_type": "Disease",
              "start_idx": 61,
              "end_idx": 64
            },
            {
              "entity_id": "T241",
              "entity": "胰腺",
              "entity_type": "Anatomy",
              "start_idx": 17,
              "end_idx": 19
            },
            {
              "entity_id": "T242",
              "entity": "胰腺",
              "entity_type": "Anatomy",
              "start_idx": 45,
              "end_idx": 47
            },
            {
              "entity_id": "T243",
              "entity": "胰腺",
              "entity_type": "Anatomy",
              "start_idx": 61,
              "end_idx": 63
            },
            {
              "entity_id": "T244",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 94,
              "end_idx": 97
            },
            {
              "entity_id": "T245",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 119,
              "end_idx": 122
            },
            {
              "entity_id": "T246",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 175,
              "end_idx": 178
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R61",
              "head_entity_id": "T231",
              "tail_entity_id": "T238"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R62",
              "head_entity_id": "T232",
              "tail_entity_id": "T238"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R63",
              "head_entity_id": "T244",
              "tail_entity_id": "T233"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R64",
              "head_entity_id": "T244",
              "tail_entity_id": "T234"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R65",
              "head_entity_id": "T245",
              "tail_entity_id": "T235"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R66",
              "head_entity_id": "T246",
              "tail_entity_id": "T236"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R67",
              "head_entity_id": "T246",
              "tail_entity_id": "T237"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R68",
              "head_entity_id": "T241",
              "tail_entity_id": "T238"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R69",
              "head_entity_id": "T242",
              "tail_entity_id": "T239"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R70",
              "head_entity_id": "T243",
              "tail_entity_id": "T240"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "39",
      "paragraph": "特殊情况",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "特殊情况",
          "start_idx": 0,
          "end_idx": 4,
          "entities": [],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "40",
      "paragraph": "(1)不适用人群",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(1)不适用人群",
          "start_idx": 0,
          "end_idx": 8,
          "entities": [],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "41",
      "paragraph": "临床应用共识给出了以下几类不适宜使用GLP-1受体激动剂的患者：",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "临床应用共识给出了以下几类不适宜使用GLP-1受体激动剂的患者：",
          "start_idx": 0,
          "end_idx": 32,
          "entities": [
            {
              "entity_id": "T247",
              "entity": "GLP-1受体激动剂",
              "entity_type": "Drug",
              "start_idx": 18,
              "end_idx": 28
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "42",
      "paragraph": "·GLP-1受体激动剂不能替代胰岛素，不适用于1型糖尿病患者或糖尿病酮症酸中毒的治疗。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "·GLP-1受体激动剂不能替代胰岛素，不适用于1型糖尿病患者或糖尿病酮症酸中毒的治疗。",
          "start_idx": 0,
          "end_idx": 43,
          "entities": [
            {
              "entity_id": "T248",
              "entity": "GLP-1受体激动剂",
              "entity_type": "Drug",
              "start_idx": 1,
              "end_idx": 11
            },
            {
              "entity_id": "T249",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 15,
              "end_idx": 18
            },
            {
              "entity_id": "T250",
              "entity": "1型糖尿病",
              "entity_type": "Disease",
              "start_idx": 23,
              "end_idx": 28
            },
            {
              "entity_id": "T251",
              "entity": "糖尿病酮症酸中毒",
              "entity_type": "Disease",
              "start_idx": 31,
              "end_idx": 39
            },
            {
              "entity_id": "T252",
              "entity": "1型",
              "entity_type": "Class",
              "start_idx": 23,
              "end_idx": 25
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R71",
              "head_entity_id": "T252",
              "tail_entity_id": "T250"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "43",
      "paragraph": "·严重胃肠道疾病患者、妊娠期和哺乳期妇女以及儿童不推荐使用。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "·严重胃肠道疾病患者、妊娠期和哺乳期妇女以及儿童不推荐使用。",
          "start_idx": 0,
          "end_idx": 30,
          "entities": [
            {
              "entity_id": "T253",
              "entity": "胃肠道疾病",
              "entity_type": "Disease",
              "start_idx": 3,
              "end_idx": 8
            },
            {
              "entity_id": "T254",
              "entity": "胃",
              "entity_type": "Anatomy",
              "start_idx": 3,
              "end_idx": 4
            },
            {
              "entity_id": "T255",
              "entity": "肠道",
              "entity_type": "Anatomy",
              "start_idx": 4,
              "end_idx": 6
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R72",
              "head_entity_id": "T254",
              "tail_entity_id": "T253"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R73",
              "head_entity_id": "T255",
              "tail_entity_id": "T253"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "44",
      "paragraph": "·艾塞那肽有罕见肾功能改变报告，不推荐用于终末期肾病或严重肾功能不全患者；利拉鲁肽由于经验有限，也不推荐用于肾脏终末期患者。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "·艾塞那肽有罕见肾功能改变报告，不推荐用于终末期肾病或严重肾功能不全患者；利拉鲁肽由于经验有限，也不推荐用于肾脏终末期患者。",
          "start_idx": 0,
          "end_idx": 62,
          "entities": [
            {
              "entity_id": "T256",
              "entity": "艾塞那肽",
              "entity_type": "Drug",
              "start_idx": 1,
              "end_idx": 5
            },
            {
              "entity_id": "T257",
              "entity": "利拉鲁肽",
              "entity_type": "Drug",
              "start_idx": 37,
              "end_idx": 41
            },
            {
              "entity_id": "T258",
              "entity": "肾功能改变",
              "entity_type": "ADE",
              "start_idx": 8,
              "end_idx": 13
            },
            {
              "entity_id": "T259",
              "entity": "肾病",
              "entity_type": "Disease",
              "start_idx": 24,
              "end_idx": 26
            },
            {
              "entity_id": "T260",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 29,
              "end_idx": 34
            },
            {
              "entity_id": "T261",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 24,
              "end_idx": 25
            },
            {
              "entity_id": "T262",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 29,
              "end_idx": 30
            },
            {
              "entity_id": "T263",
              "entity": "终末期",
              "entity_type": "Class",
              "start_idx": 21,
              "end_idx": 24
            },
            {
              "entity_id": "T264",
              "entity": "严重",
              "entity_type": "Level",
              "start_idx": 27,
              "end_idx": 29
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R74",
              "head_entity_id": "T258",
              "tail_entity_id": "T256"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R75",
              "head_entity_id": "T261",
              "tail_entity_id": "T259"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R76",
              "head_entity_id": "T263",
              "tail_entity_id": "T259"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R77",
              "head_entity_id": "T262",
              "tail_entity_id": "T260"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "45",
      "paragraph": "·利拉鲁肽在纽约心脏病学会(NYHA)分级l-II级的充血性心力衰竭的患者中的治疗经验有限，尚无在III一IV级充血性心力衰竭患者中的应用经验。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "·利拉鲁肽在纽约心脏病学会(NYHA)分级l-II级的充血性心力衰竭的患者中的治疗经验有限，尚无在III一IV级充血性心力衰竭患者中的应用经验。",
          "start_idx": 0,
          "end_idx": 72,
          "entities": [
            {
              "entity_id": "T265",
              "entity": "利拉鲁肽",
              "entity_type": "Drug",
              "start_idx": 1,
              "end_idx": 5
            },
            {
              "entity_id": "T266",
              "entity": "充血性心力衰竭",
              "entity_type": "Disease",
              "start_idx": 27,
              "end_idx": 34
            },
            {
              "entity_id": "T267",
              "entity": "充血性心力衰竭",
              "entity_type": "Disease",
              "start_idx": 56,
              "end_idx": 63
            },
            {
              "entity_id": "T268",
              "entity": "l-II级",
              "entity_type": "Class",
              "start_idx": 21,
              "end_idx": 26
            },
            {
              "entity_id": "T269",
              "entity": "III一IV级",
              "entity_type": "Class",
              "start_idx": 49,
              "end_idx": 56
            },
            {
              "entity_id": "T270",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 30,
              "end_idx": 31
            },
            {
              "entity_id": "T271",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 59,
              "end_idx": 60
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R78",
              "head_entity_id": "T265",
              "tail_entity_id": "T266"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R79",
              "head_entity_id": "T268",
              "tail_entity_id": "T266"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R80",
              "head_entity_id": "T270",
              "tail_entity_id": "T266"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R81",
              "head_entity_id": "T269",
              "tail_entity_id": "T267"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R82",
              "head_entity_id": "T271",
              "tail_entity_id": "T267"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "46",
      "paragraph": "·利拉鲁肽不得用于有甲状腺髓样癌(MTC)既往史或家族史患者以及2型多发性内分泌肿瘤综合征患者。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "·利拉鲁肽不得用于有甲状腺髓样癌(MTC)既往史或家族史患者以及2型多发性内分泌肿瘤综合征患者。",
          "start_idx": 0,
          "end_idx": 48,
          "entities": [
            {
              "entity_id": "T272",
              "entity": "利拉鲁肽",
              "entity_type": "Drug",
              "start_idx": 1,
              "end_idx": 5
            },
            {
              "entity_id": "T273",
              "entity": "甲状腺髓样癌(MTC)",
              "entity_type": "Disease",
              "start_idx": 10,
              "end_idx": 21
            },
            {
              "entity_id": "T274",
              "entity": "2型多发性内分泌肿瘤综合征",
              "entity_type": "Disease",
              "start_idx": 32,
              "end_idx": 45
            },
            {
              "entity_id": "T275",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 32,
              "end_idx": 34
            },
            {
              "entity_id": "T276",
              "entity": "甲状腺",
              "entity_type": "Anatomy",
              "start_idx": 10,
              "end_idx": 13
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R83",
              "head_entity_id": "T276",
              "tail_entity_id": "T273"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R84",
              "head_entity_id": "T275",
              "tail_entity_id": "T274"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "47",
      "paragraph": "·禁用于对该类产品活性成分或任何其他辅料过敏者。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "·禁用于对该类产品活性成分或任何其他辅料过敏者。",
          "start_idx": 0,
          "end_idx": 24,
          "entities": [],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "48",
      "paragraph": "(2)额外获益人群",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(2)额外获益人群",
          "start_idx": 0,
          "end_idx": 9,
          "entities": [],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "49",
      "paragraph": "快速建议指南指出，以下人群更加适合使用GLP-1受体激动剂：",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "快速建议指南指出，以下人群更加适合使用GLP-1受体激动剂：",
          "start_idx": 0,
          "end_idx": 30,
          "entities": [
            {
              "entity_id": "T277",
              "entity": "GLP-1受体激动剂",
              "entity_type": "Drug",
              "start_idx": 19,
              "end_idx": 29
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "50",
      "paragraph": "·由于GLP-1受体激动剂可显著降低患者体重，对于超重肥胖的2型糖尿病患者，建议用于超重/肥胖患者的降糖治疗。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "·由于GLP-1受体激动剂可显著降低患者体重，对于超重肥胖的2型糖尿病患者，建议用于超重/肥胖患者的降糖治疗。",
          "start_idx": 0,
          "end_idx": 55,
          "entities": [
            {
              "entity_id": "T278",
              "entity": "GLP-1受体激动剂",
              "entity_type": "Drug",
              "start_idx": 3,
              "end_idx": 13
            },
            {
              "entity_id": "T279",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 30,
              "end_idx": 35
            },
            {
              "entity_id": "T280",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 30,
              "end_idx": 32
            },
            {
              "entity_id": "T281",
              "entity": "超重",
              "entity_type": "Disease",
              "start_idx": 42,
              "end_idx": 44
            },
            {
              "entity_id": "T282",
              "entity": "肥胖",
              "entity_type": "Disease",
              "start_idx": 45,
              "end_idx": 47
            },
            {
              "entity_id": "T283",
              "entity": "超重",
              "entity_type": "Disease",
              "start_idx": 25,
              "end_idx": 27
            },
            {
              "entity_id": "T284",
              "entity": "肥胖",
              "entity_type": "Disease",
              "start_idx": 27,
              "end_idx": 29
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R85",
              "head_entity_id": "T278",
              "tail_entity_id": "T283"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R86",
              "head_entity_id": "T278",
              "tail_entity_id": "T284"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R87",
              "head_entity_id": "T278",
              "tail_entity_id": "T279"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R88",
              "head_entity_id": "T278",
              "tail_entity_id": "T281"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R89",
              "head_entity_id": "T278",
              "tail_entity_id": "T282"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "51",
      "paragraph": "·对于伴有非酒精性脂肪肝的2型糖尿病患者，GL-1受体激动剂可降低体质指数(BMl)和转氨酶ALT水平，建议使用GLP-1受体激动剂进行治疗。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "·对于伴有非酒精性脂肪肝的2型糖尿病患者，GL-1受体激动剂可降低体质指数(BMl)和转氨酶ALT水平，建议使用GLP-1受体激动剂进行治疗。",
          "start_idx": 0,
          "end_idx": 71,
          "entities": [
            {
              "entity_id": "T285",
              "entity": "GL-1受体激动剂",
              "entity_type": "Drug",
              "start_idx": 21,
              "end_idx": 30
            },
            {
              "entity_id": "T286",
              "entity": "GLP-1受体激动剂",
              "entity_type": "Drug",
              "start_idx": 56,
              "end_idx": 66
            },
            {
              "entity_id": "T287",
              "entity": "非酒精性脂肪肝",
              "entity_type": "Disease",
              "start_idx": 5,
              "end_idx": 12
            },
            {
              "entity_id": "T288",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 13,
              "end_idx": 18
            },
            {
              "entity_id": "T289",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 13,
              "end_idx": 15
            },
            {
              "entity_id": "T290",
              "entity": "转氨酶ALT",
              "entity_type": "Test_items",
              "start_idx": 43,
              "end_idx": 49
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R90",
              "head_entity_id": "T285",
              "tail_entity_id": "T287"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R91",
              "head_entity_id": "T285",
              "tail_entity_id": "T288"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R92",
              "head_entity_id": "T289",
              "tail_entity_id": "T288"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R93",
              "head_entity_id": "T290",
              "tail_entity_id": "T288"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "52",
      "paragraph": "钠-葡萄糖共转运蛋白2抑制剂：(《钠-葡萄糖共转运蛋白2(SGLT-2)抑制剂临床合理应用中国专家建议》)",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "钠-葡萄糖共转运蛋白2抑制剂：(《钠-葡萄糖共转运蛋白2(SGLT-2)抑制剂临床合理应用中国专家建议》)",
          "start_idx": 0,
          "end_idx": 53,
          "entities": [
            {
              "entity_id": "T291",
              "entity": "钠-葡萄糖共转运蛋白2抑制剂",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 14
            },
            {
              "entity_id": "T292",
              "entity": "钠-葡萄糖共转运蛋白2(SGLT-2)抑制剂",
              "entity_type": "Drug",
              "start_idx": 17,
              "end_idx": 39
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "53",
      "paragraph": "钠-葡萄糖共转运蛋白2抑制剂是一种非常特殊的口服降糖药物，说它特殊是因为，与其他降糖药物都不同的是，它并没有从胰腺、胃肠道等调节血糖的内分泌器官入手，而是作用于葡萄糖的排泄器官一肾脏，通过让更多葡萄糖经肾脏从尿液排出体外来达到降低血糖的效果。大家都知道，只有血糖水平超过肾糖阈时，血中多余的葡萄糖才会从肾脏排泄，这也是血糖需要达到较高水平时尿糖试纸才会有反应的原因。然而，随着研究的深入，人们发现，SGLT-2抑制剂并不仅仅是通过降低肾糖阈来促进葡萄糖经尿排出，它还具有明显的减重效果，并且可降低血压、尿酸水平，减少尿蛋白排泄，降低甘油三酯，同时升高高密度脂蛋白胆固醇(HDL-C)和低密度脂蛋白胆固醇(LDL-C)，但不增加LDL/HDL比值。因此，SGLT-2抑制剂这两年也成为临床研究和学术会议的热点。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "钠-葡萄糖共转运蛋白2抑制剂是一种非常特殊的口服降糖药物，说它特殊是因为，与其他降糖药物都不同的是，它并没有从胰腺、胃肠道等调节血糖的内分泌器官入手，而是作用于葡萄糖的排泄器官一肾脏，通过让更多葡萄糖经肾脏从尿液排出体外来达到降低血糖的效果。",
          "start_idx": 0,
          "end_idx": 121,
          "entities": [
            {
              "entity_id": "T293",
              "entity": "钠-葡萄糖共转运蛋白2抑制剂",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 14
            },
            {
              "entity_id": "T294",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 22,
              "end_idx": 24
            },
            {
              "entity_id": "T295",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 64,
              "end_idx": 66
            },
            {
              "entity_id": "T300",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 115,
              "end_idx": 117
            }
          ],
          "relations": [
            {
              "relation_type": "Method_Drug",
              "relation_id": "R94",
              "head_entity_id": "T294",
              "tail_entity_id": "T293"
            }
          ]
        },
        {
          "sentence_id": "1",
          "sentence": "大家都知道，只有血糖水平超过肾糖阈时，血中多余的葡萄糖才会从肾脏排泄，这也是血糖需要达到较高水平时尿糖试纸才会有反应的原因。",
          "start_idx": 121,
          "end_idx": 183,
          "entities": [
            {
              "entity_id": "T296",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 8,
              "end_idx": 10
            },
            {
              "entity_id": "T297",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 38,
              "end_idx": 40
            }
          ],
          "relations": []
        },
        {
          "sentence_id": "2",
          "sentence": "然而，随着研究的深入，人们发现，SGLT-2抑制剂并不仅仅是通过降低肾糖阈来促进葡萄糖经尿排出，它还具有明显的减重效果，并且可降低血压、尿酸水平，减少尿蛋白排泄，降低甘油三酯，同时升高高密度脂蛋白胆固醇(HDL-C)和低密度脂蛋白胆固醇(LDL-C)，但不增加LDL/HDL比值。",
          "start_idx": 183,
          "end_idx": 323,
          "entities": [
            {
              "entity_id": "T298",
              "entity": "SGLT-2抑制剂",
              "entity_type": "Drug",
              "start_idx": 16,
              "end_idx": 25
            },
            {
              "entity_id": "T301",
              "entity": "甘油三酯",
              "entity_type": "Test_items",
              "start_idx": 83,
              "end_idx": 87
            },
            {
              "entity_id": "T302",
              "entity": "血压",
              "entity_type": "Test_items",
              "start_idx": 65,
              "end_idx": 67
            },
            {
              "entity_id": "T303",
              "entity": "尿酸",
              "entity_type": "Test_items",
              "start_idx": 68,
              "end_idx": 70
            },
            {
              "entity_id": "T304",
              "entity": "高密度脂蛋白胆固醇(HDL-C)",
              "entity_type": "Test_items",
              "start_idx": 92,
              "end_idx": 108
            },
            {
              "entity_id": "T305",
              "entity": "低密度脂蛋白胆固醇(LDL-C)",
              "entity_type": "Test_items",
              "start_idx": 109,
              "end_idx": 125
            },
            {
              "entity_id": "T306",
              "entity": "LDL/HDL比值",
              "entity_type": "Test_items",
              "start_idx": 130,
              "end_idx": 139
            },
            {
              "entity_id": "T307",
              "entity": "尿蛋白",
              "entity_type": "Test_items",
              "start_idx": 75,
              "end_idx": 78
            }
          ],
          "relations": []
        },
        {
          "sentence_id": "3",
          "sentence": "因此，SGLT-2抑制剂这两年也成为临床研究和学术会议的热点。",
          "start_idx": 323,
          "end_idx": 354,
          "entities": [
            {
              "entity_id": "T299",
              "entity": "SGLT-2抑制剂",
              "entity_type": "Drug",
              "start_idx": 3,
              "end_idx": 12
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "54",
      "paragraph": "目前，已经有多个SGLT-2抑制剂及其复方制剂在国外上市，并得到越来越多的临床应用。《钠-葡萄糖共转运蛋白2(SGLT-2)抑制剂临床合理应用中国专家建议》(简称中国建议)发布的时候，我国还没有SGLT-2抑制剂获批上市，但在今年，中国国家食品药品监督管理总局(CFDA)一连批准了两个SGLT-2抑制剂上市，先是在3月份批准达格列净上市，接着在9月份有批准恩格列净上市。相信随着来自中国人群的临床应用证据越来越多，中国建议还将不断完善。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "目前，已经有多个SGLT-2抑制剂及其复方制剂在国外上市，并得到越来越多的临床应用。",
          "start_idx": 0,
          "end_idx": 42,
          "entities": [
            {
              "entity_id": "T308",
              "entity": "SGLT-2抑制剂",
              "entity_type": "Drug",
              "start_idx": 8,
              "end_idx": 17
            }
          ],
          "relations": []
        },
        {
          "sentence_id": "1",
          "sentence": "《钠-葡萄糖共转运蛋白2(SGLT-2)抑制剂临床合理应用中国专家建议》(简称中国建议)发布的时候，我国还没有SGLT-2抑制剂获批上市，但在今年，中国国家食品药品监督管理总局(CFDA)一连批准了两个SGLT-2抑制剂上市，先是在3月份批准达格列净上市，接着在9月份有批准恩格列净上市。",
          "start_idx": 42,
          "end_idx": 186,
          "entities": [
            {
              "entity_id": "T309",
              "entity": "SGLT-2抑制剂",
              "entity_type": "Drug",
              "start_idx": 55,
              "end_idx": 64
            },
            {
              "entity_id": "T310",
              "entity": "SGLT-2抑制剂",
              "entity_type": "Drug",
              "start_idx": 101,
              "end_idx": 110
            },
            {
              "entity_id": "T311",
              "entity": "达格列净",
              "entity_type": "Drug",
              "start_idx": 121,
              "end_idx": 125
            },
            {
              "entity_id": "T312",
              "entity": "恩格列净",
              "entity_type": "Drug",
              "start_idx": 137,
              "end_idx": 141
            },
            {
              "entity_id": "T313",
              "entity": "钠-葡萄糖共转运蛋白2(SGLT-2)抑制剂",
              "entity_type": "Drug",
              "start_idx": 1,
              "end_idx": 23
            }
          ],
          "relations": []
        },
        {
          "sentence_id": "2",
          "sentence": "相信随着来自中国人群的临床应用证据越来越多，中国建议还将不断完善。",
          "start_idx": 186,
          "end_idx": 219,
          "entities": [],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "55",
      "paragraph": "适用人群",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "适用人群",
          "start_idx": 0,
          "end_idx": 4,
          "entities": [],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "56",
      "paragraph": "中国建议指出，SGLT-2抑制剂可应用于成人2型糖尿病，当饮食和运动不能使血糖得到满意控制或二甲双胍不能耐受时，可单独使用，也可与其他口服降糖药物及胰岛素联合使用。由于SGLT-2抑制剂的药理作用依赖于一定水平的肾小球滤过率，所以要求患者的估算肾小球滤过率(eGFR)>60或45mI/(min·1.73m2)。CFDA批准的达格列净说明书上所写的适应证为“在饮食和运动基础上，本品可作为单药治疗用于2型糖尿病成人患者改善血糖控制。”目前，SGLT-2抑制剂未被批准用于1型糖尿病；儿童青少年及孕妇和哺乳期妇女中无使用SGLT-2抑制剂的数据，故暂不推荐在此类人群中使用。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "中国建议指出，SGLT-2抑制剂可应用于成人2型糖尿病，当饮食和运动不能使血糖得到满意控制或二甲双胍不能耐受时，可单独使用，也可与其他口服降糖药物及胰岛素联合使用。",
          "start_idx": 0,
          "end_idx": 82,
          "entities": [
            {
              "entity_id": "T314",
              "entity": "SGLT-2抑制剂",
              "entity_type": "Drug",
              "start_idx": 7,
              "end_idx": 16
            },
            {
              "entity_id": "T315",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 46,
              "end_idx": 50
            },
            {
              "entity_id": "T316",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 74,
              "end_idx": 77
            },
            {
              "entity_id": "T320",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 22,
              "end_idx": 27
            },
            {
              "entity_id": "T324",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 22,
              "end_idx": 24
            },
            {
              "entity_id": "T330",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 37,
              "end_idx": 39
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R95",
              "head_entity_id": "T314",
              "tail_entity_id": "T320"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R96",
              "head_entity_id": "T316",
              "tail_entity_id": "T320"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R97",
              "head_entity_id": "T324",
              "tail_entity_id": "T320"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R98",
              "head_entity_id": "T330",
              "tail_entity_id": "T320"
            }
          ]
        },
        {
          "sentence_id": "1",
          "sentence": "由于SGLT-2抑制剂的药理作用依赖于一定水平的肾小球滤过率，所以要求患者的估算肾小球滤过率(eGFR)>60或45mI/(min·1.73m2)。",
          "start_idx": 82,
          "end_idx": 156,
          "entities": [
            {
              "entity_id": "T317",
              "entity": "SGLT-2抑制剂",
              "entity_type": "Drug",
              "start_idx": 2,
              "end_idx": 11
            },
            {
              "entity_id": "T327",
              "entity": "肾小球滤过率",
              "entity_type": "Test_items",
              "start_idx": 24,
              "end_idx": 30
            },
            {
              "entity_id": "T328",
              "entity": "肾小球滤过率(eGFR)",
              "entity_type": "Test_items",
              "start_idx": 40,
              "end_idx": 52
            },
            {
              "entity_id": "T329",
              "entity": ">60或45mI/(min·1.73m2)",
              "entity_type": "Test_Value",
              "start_idx": 52,
              "end_idx": 73
            }
          ],
          "relations": []
        },
        {
          "sentence_id": "2",
          "sentence": "CFDA批准的达格列净说明书上所写的适应证为“在饮食和运动基础上，本品可作为单药治疗用于2型糖尿病成人患者改善血糖控制。",
          "start_idx": 156,
          "end_idx": 216,
          "entities": [
            {
              "entity_id": "T321",
              "entity": "达格列净",
              "entity_type": "Drug",
              "start_idx": 7,
              "end_idx": 11
            },
            {
              "entity_id": "T322",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 44,
              "end_idx": 49
            },
            {
              "entity_id": "T325",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 44,
              "end_idx": 46
            },
            {
              "entity_id": "T331",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 55,
              "end_idx": 57
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R99",
              "head_entity_id": "T325",
              "tail_entity_id": "T322"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R100",
              "head_entity_id": "T331",
              "tail_entity_id": "T322"
            }
          ]
        },
        {
          "sentence_id": "3",
          "sentence": "”目前，SGLT-2抑制剂未被批准用于1型糖尿病；儿童青少年及孕妇和哺乳期妇女中无使用SGLT-2抑制剂的数据，故暂不推荐在此类人群中使用。",
          "start_idx": 216,
          "end_idx": 286,
          "entities": [
            {
              "entity_id": "T318",
              "entity": "SGLT-2抑制剂",
              "entity_type": "Drug",
              "start_idx": 4,
              "end_idx": 13
            },
            {
              "entity_id": "T319",
              "entity": "SGLT-2抑制剂",
              "entity_type": "Drug",
              "start_idx": 43,
              "end_idx": 52
            },
            {
              "entity_id": "T323",
              "entity": "1型糖尿病",
              "entity_type": "Disease",
              "start_idx": 19,
              "end_idx": 24
            },
            {
              "entity_id": "T326",
              "entity": "1型",
              "entity_type": "Class",
              "start_idx": 19,
              "end_idx": 21
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R101",
              "head_entity_id": "T326",
              "tail_entity_id": "T323"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "57",
      "paragraph": "临床用法",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "临床用法",
          "start_idx": 0,
          "end_idx": 4,
          "entities": [],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "58",
      "paragraph": "(1)用量",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(1)用量",
          "start_idx": 0,
          "end_idx": 5,
          "entities": [],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "60",
      "paragraph": "CFDA批准的达格列净剂量规格为5毫克和10毫克两种，说明书给出的用量是，推荐起始剂量为5毫克每日一次，对于需加强血糖控制且耐受5毫克每日一次的患者，可增加至10毫克每日一次。CFDA批准的恩格列净剂量规格只有10毫克一种，所以10毫克起始，最大剂量可能为20毫克(目前尚未得到恩格列净说明书)。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "CFDA批准的达格列净剂量规格为5毫克和10毫克两种，说明书给出的用量是，推荐起始剂量为5毫克每日一次，对于需加强血糖控制且耐受5毫克每日一次的患者，可增加至10毫克每日一次。",
          "start_idx": 0,
          "end_idx": 88,
          "entities": [
            {
              "entity_id": "T332",
              "entity": "达格列净",
              "entity_type": "Drug",
              "start_idx": 7,
              "end_idx": 11
            },
            {
              "entity_id": "T335",
              "entity": "5毫克",
              "entity_type": "Amount",
              "start_idx": 44,
              "end_idx": 47
            },
            {
              "entity_id": "T336",
              "entity": "5毫克",
              "entity_type": "Amount",
              "start_idx": 64,
              "end_idx": 67
            },
            {
              "entity_id": "T337",
              "entity": "10毫克",
              "entity_type": "Amount",
              "start_idx": 79,
              "end_idx": 83
            },
            {
              "entity_id": "T340",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 57,
              "end_idx": 59
            },
            {
              "entity_id": "T341",
              "entity": "每日一次",
              "entity_type": "Frequency",
              "start_idx": 83,
              "end_idx": 87
            },
            {
              "entity_id": "T342",
              "entity": "每日一次",
              "entity_type": "Frequency",
              "start_idx": 47,
              "end_idx": 51
            }
          ],
          "relations": [
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R102",
              "head_entity_id": "T335",
              "tail_entity_id": "T332"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R103",
              "head_entity_id": "T336",
              "tail_entity_id": "T332"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R104",
              "head_entity_id": "T337",
              "tail_entity_id": "T332"
            },
            {
              "relation_type": "Frequency_Drug",
              "relation_id": "R105",
              "head_entity_id": "T341",
              "tail_entity_id": "T332"
            },
            {
              "relation_type": "Frequency_Drug",
              "relation_id": "R106",
              "head_entity_id": "T342",
              "tail_entity_id": "T332"
            }
          ]
        },
        {
          "sentence_id": "1",
          "sentence": "CFDA批准的恩格列净剂量规格只有10毫克一种，所以10毫克起始，最大剂量可能为20毫克(目前尚未得到恩格列净说明书)。",
          "start_idx": 88,
          "end_idx": 148,
          "entities": [
            {
              "entity_id": "T333",
              "entity": "恩格列净",
              "entity_type": "Drug",
              "start_idx": 7,
              "end_idx": 11
            },
            {
              "entity_id": "T334",
              "entity": "恩格列净",
              "entity_type": "Drug",
              "start_idx": 51,
              "end_idx": 55
            },
            {
              "entity_id": "T338",
              "entity": "20毫克",
              "entity_type": "Amount",
              "start_idx": 40,
              "end_idx": 44
            },
            {
              "entity_id": "T339",
              "entity": "10毫克",
              "entity_type": "Amount",
              "start_idx": 26,
              "end_idx": 30
            }
          ],
          "relations": [
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R107",
              "head_entity_id": "T339",
              "tail_entity_id": "T333"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R108",
              "head_entity_id": "T338",
              "tail_entity_id": "T333"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "61",
      "paragraph": "(2)用法",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(2)用法",
          "start_idx": 0,
          "end_idx": 5,
          "entities": [],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "62",
      "paragraph": "此类药物均只需晨服一次即可，达格列净和恩格列净餐前或餐后均可服用。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "此类药物均只需晨服一次即可，达格列净和恩格列净餐前或餐后均可服用。",
          "start_idx": 0,
          "end_idx": 33,
          "entities": [
            {
              "entity_id": "T343",
              "entity": "达格列净",
              "entity_type": "Drug",
              "start_idx": 14,
              "end_idx": 18
            },
            {
              "entity_id": "T344",
              "entity": "恩格列净",
              "entity_type": "Drug",
              "start_idx": 19,
              "end_idx": 23
            },
            {
              "entity_id": "T345",
              "entity": "一次",
              "entity_type": "Frequency",
              "start_idx": 9,
              "end_idx": 11
            }
          ],
          "relations": [
            {
              "relation_type": "Frequency_Drug",
              "relation_id": "R109",
              "head_entity_id": "T345",
              "tail_entity_id": "T343"
            },
            {
              "relation_type": "Frequency_Drug",
              "relation_id": "R110",
              "head_entity_id": "T345",
              "tail_entity_id": "T344"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "63",
      "paragraph": "(3)不良反应处理",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(3)不良反应处理",
          "start_idx": 0,
          "end_idx": 9,
          "entities": [],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "64",
      "paragraph": "A.泌尿生殖道感染由于此类药物促进大量葡萄糖从尿液排出，这就增加了泌尿生殖道局部的葡萄糖浓度，导致发生细菌和霉菌感染的机会增加。临床研究数据显示，SGLT-2抑制剂治疗后生殖道感染发生率为4.8%~5.7%，但多为轻到中度感染，常规抗感染治疗有效；女性较男性生殖道感染发生率稍高；有感染疾病史者感染率升高，且感染后需抗感染治疗。女性生殖道感染大部分发生在用药的初始4个月内，最常见的是外阴阴道真菌感染、阴道念珠菌病和外阴阴道炎；男性生殖道感染大部分发生在用药第一年内，最常见的是念珠菌性龟头炎和阴茎包皮炎。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "A.泌尿生殖道感染由于此类药物促进大量葡萄糖从尿液排出，这就增加了泌尿生殖道局部的葡萄糖浓度，导致发生细菌和霉菌感染的机会增加。临床研究数据显示，SGLT-2抑制剂治疗后生殖道感染发生率为4.8%~5.7%，但多为轻到中度感染，常规抗感染治疗有效；女性较男性生殖道感染发生率稍高；有感染疾病史者感染率升高，且感染后需抗感染治疗。",
          "start_idx": 0,
          "end_idx": 164,
          "entities": [
            {
              "entity_id": "T346",
              "entity": "泌尿生殖道感染",
              "entity_type": "Disease",
              "start_idx": 2,
              "end_idx": 9
            },
            {
              "entity_id": "T347",
              "entity": "SGLT-2抑制剂",
              "entity_type": "Drug",
              "start_idx": 73,
              "end_idx": 82
            },
            {
              "entity_id": "T348",
              "entity": "生殖道感染",
              "entity_type": "Disease",
              "start_idx": 85,
              "end_idx": 90
            },
            {
              "entity_id": "T349",
              "entity": "感染",
              "entity_type": "Disease",
              "start_idx": 111,
              "end_idx": 113
            },
            {
              "entity_id": "T350",
              "entity": "生殖道感染",
              "entity_type": "Disease",
              "start_idx": 129,
              "end_idx": 134
            },
            {
              "entity_id": "T351",
              "entity": "感染疾病",
              "entity_type": "Disease",
              "start_idx": 141,
              "end_idx": 145
            },
            {
              "entity_id": "T352",
              "entity": "感染",
              "entity_type": "Disease",
              "start_idx": 154,
              "end_idx": 156
            },
            {
              "entity_id": "T360",
              "entity": "生殖道",
              "entity_type": "Anatomy",
              "start_idx": 4,
              "end_idx": 7
            },
            {
              "entity_id": "T361",
              "entity": "生殖道",
              "entity_type": "Anatomy",
              "start_idx": 85,
              "end_idx": 88
            },
            {
              "entity_id": "T362",
              "entity": "生殖道",
              "entity_type": "Anatomy",
              "start_idx": 129,
              "end_idx": 132
            },
            {
              "entity_id": "T370",
              "entity": "轻到中度",
              "entity_type": "Level",
              "start_idx": 107,
              "end_idx": 111
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R111",
              "head_entity_id": "T360",
              "tail_entity_id": "T346"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R112",
              "head_entity_id": "T361",
              "tail_entity_id": "T348"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R113",
              "head_entity_id": "T362",
              "tail_entity_id": "T350"
            }
          ]
        },
        {
          "sentence_id": "1",
          "sentence": "女性生殖道感染大部分发生在用药的初始4个月内，最常见的是外阴阴道真菌感染、阴道念珠菌病和外阴阴道炎；男性生殖道感染大部分发生在用药第一年内，最常见的是念珠菌性龟头炎和阴茎包皮炎。",
          "start_idx": 164,
          "end_idx": 253,
          "entities": [
            {
              "entity_id": "T353",
              "entity": "生殖道感染",
              "entity_type": "Disease",
              "start_idx": 2,
              "end_idx": 7
            },
            {
              "entity_id": "T354",
              "entity": "外阴阴道真菌感染",
              "entity_type": "Disease",
              "start_idx": 28,
              "end_idx": 36
            },
            {
              "entity_id": "T355",
              "entity": "阴道念珠菌病",
              "entity_type": "Disease",
              "start_idx": 37,
              "end_idx": 43
            },
            {
              "entity_id": "T356",
              "entity": "外阴阴道炎",
              "entity_type": "Disease",
              "start_idx": 44,
              "end_idx": 49
            },
            {
              "entity_id": "T357",
              "entity": "生殖道感染",
              "entity_type": "Disease",
              "start_idx": 52,
              "end_idx": 57
            },
            {
              "entity_id": "T358",
              "entity": "念珠菌性龟头炎",
              "entity_type": "Disease",
              "start_idx": 75,
              "end_idx": 82
            },
            {
              "entity_id": "T359",
              "entity": "阴茎包皮炎",
              "entity_type": "Disease",
              "start_idx": 83,
              "end_idx": 88
            },
            {
              "entity_id": "T363",
              "entity": "生殖道",
              "entity_type": "Anatomy",
              "start_idx": 2,
              "end_idx": 5
            },
            {
              "entity_id": "T364",
              "entity": "外阴阴道",
              "entity_type": "Anatomy",
              "start_idx": 28,
              "end_idx": 32
            },
            {
              "entity_id": "T365",
              "entity": "阴道",
              "entity_type": "Anatomy",
              "start_idx": 37,
              "end_idx": 39
            },
            {
              "entity_id": "T366",
              "entity": "外阴阴道",
              "entity_type": "Anatomy",
              "start_idx": 44,
              "end_idx": 48
            },
            {
              "entity_id": "T367",
              "entity": "生殖道",
              "entity_type": "Anatomy",
              "start_idx": 52,
              "end_idx": 55
            },
            {
              "entity_id": "T368",
              "entity": "龟头",
              "entity_type": "Anatomy",
              "start_idx": 79,
              "end_idx": 81
            },
            {
              "entity_id": "T369",
              "entity": "阴茎包皮",
              "entity_type": "Anatomy",
              "start_idx": 83,
              "end_idx": 87
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R114",
              "head_entity_id": "T363",
              "tail_entity_id": "T353"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R115",
              "head_entity_id": "T364",
              "tail_entity_id": "T354"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R116",
              "head_entity_id": "T365",
              "tail_entity_id": "T355"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R117",
              "head_entity_id": "T366",
              "tail_entity_id": "T356"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R118",
              "head_entity_id": "T367",
              "tail_entity_id": "T357"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R119",
              "head_entity_id": "T368",
              "tail_entity_id": "T358"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R120",
              "head_entity_id": "T369",
              "tail_entity_id": "T359"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "65",
      "paragraph": "【应对】为避免生殖道和泌尿道感染发生，建议使用前询问病史，半年内反复发生泌尿生殖感染的患者不推荐使用；在使用过程中，如发生感染并需要抗感染治疗时建议暂时停药，感染治愈后，可继续使用。使用过程中，尤其是第一个月，需要关注是否出现感染的症状和体征，如出现，应及时就医并作相关检查以明确有无感染。患者在使用此类药物过程中，还应当注意个人外阴部卫生，适量饮水，保持小便通畅，减少感染发生。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "【应对】为避免生殖道和泌尿道感染发生，建议使用前询问病史，半年内反复发生泌尿生殖感染的患者不推荐使用；在使用过程中，如发生感染并需要抗感染治疗时建议暂时停药，感染治愈后，可继续使用。使用过程中，尤其是第一个月，需要关注是否出现感染的症状和体征，如出现，应及时就医并作相关检查以明确有无感染。患者在使用此类药物过程中，还应当注意个人外阴部卫生，适量饮水，保持小便通畅，减少感染发生。",
          "start_idx": 0,
          "end_idx": 190,
          "entities": [
            {
              "entity_id": "T371",
              "entity": "生殖道和泌尿道感染",
              "entity_type": "Disease",
              "start_idx": 7,
              "end_idx": 16
            },
            {
              "entity_id": "T372",
              "entity": "泌尿生殖感染",
              "entity_type": "Disease",
              "start_idx": 36,
              "end_idx": 42
            },
            {
              "entity_id": "T373",
              "entity": "感染",
              "entity_type": "Disease",
              "start_idx": 61,
              "end_idx": 63
            },
            {
              "entity_id": "T374",
              "entity": "感染",
              "entity_type": "Disease",
              "start_idx": 113,
              "end_idx": 115
            },
            {
              "entity_id": "T375",
              "entity": "感染",
              "entity_type": "Disease",
              "start_idx": 142,
              "end_idx": 144
            },
            {
              "entity_id": "T376",
              "entity": "感染",
              "entity_type": "Disease",
              "start_idx": 185,
              "end_idx": 187
            },
            {
              "entity_id": "T377",
              "entity": "生殖道",
              "entity_type": "Anatomy",
              "start_idx": 7,
              "end_idx": 10
            },
            {
              "entity_id": "T378",
              "entity": "泌尿道",
              "entity_type": "Anatomy",
              "start_idx": 11,
              "end_idx": 14
            },
            {
              "entity_id": "T379",
              "entity": "泌尿",
              "entity_type": "Anatomy",
              "start_idx": 36,
              "end_idx": 38
            },
            {
              "entity_id": "T380",
              "entity": "生殖",
              "entity_type": "Anatomy",
              "start_idx": 38,
              "end_idx": 40
            },
            {
              "entity_id": "T381",
              "entity": "注意个人外阴部卫生",
              "entity_type": "Treatment",
              "start_idx": 161,
              "end_idx": 170
            },
            {
              "entity_id": "T382",
              "entity": "适量饮水",
              "entity_type": "Treatment",
              "start_idx": 171,
              "end_idx": 175
            },
            {
              "entity_id": "T383",
              "entity": "保持小便通畅",
              "entity_type": "Treatment",
              "start_idx": 176,
              "end_idx": 182
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R121",
              "head_entity_id": "T377",
              "tail_entity_id": "T371"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R122",
              "head_entity_id": "T378",
              "tail_entity_id": "T371"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R123",
              "head_entity_id": "T379",
              "tail_entity_id": "T372"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R124",
              "head_entity_id": "T380",
              "tail_entity_id": "T372"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R125",
              "head_entity_id": "T381",
              "tail_entity_id": "T376"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R126",
              "head_entity_id": "T382",
              "tail_entity_id": "T376"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R127",
              "head_entity_id": "T383",
              "tail_entity_id": "T376"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "66",
      "paragraph": "B.低血糖S GLT-2抑制剂单药治疗不增加低血糖风险；与二甲双胍、DPP-4抑制剂、噻唑烷二酮类等药物联用时，低血糖风险也没有明显增加；与胰岛素或磺脲类药物联用时低血糖风险增加。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "B.低血糖S GLT-2抑制剂单药治疗不增加低血糖风险；与二甲双胍、DPP-4抑制剂、噻唑烷二酮类等药物联用时，低血糖风险也没有明显增加；与胰岛素或磺脲类药物联用时低血糖风险增加。",
          "start_idx": 0,
          "end_idx": 90,
          "entities": [
            {
              "entity_id": "T384",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 29,
              "end_idx": 33
            },
            {
              "entity_id": "T385",
              "entity": "DPP-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 34,
              "end_idx": 42
            },
            {
              "entity_id": "T386",
              "entity": "噻唑烷二酮类",
              "entity_type": "Drug",
              "start_idx": 43,
              "end_idx": 49
            },
            {
              "entity_id": "T387",
              "entity": "S GLT-2抑制剂",
              "entity_type": "Drug",
              "start_idx": 5,
              "end_idx": 15
            },
            {
              "entity_id": "T388",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 70,
              "end_idx": 73
            },
            {
              "entity_id": "T389",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 74,
              "end_idx": 79
            },
            {
              "entity_id": "T390",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 2,
              "end_idx": 5
            },
            {
              "entity_id": "T391",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 22,
              "end_idx": 25
            },
            {
              "entity_id": "T392",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 56,
              "end_idx": 59
            },
            {
              "entity_id": "T393",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 82,
              "end_idx": 85
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R128",
              "head_entity_id": "T393",
              "tail_entity_id": "T387"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R129",
              "head_entity_id": "T393",
              "tail_entity_id": "T388"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R130",
              "head_entity_id": "T393",
              "tail_entity_id": "T389"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "67",
      "paragraph": "【应对】与胰岛素或磺脲类药物联用时，要注意调整胰岛素或磺脲类药物剂量，加强血糖监测，避免低血糖发生。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "【应对】与胰岛素或磺脲类药物联用时，要注意调整胰岛素或磺脲类药物剂量，加强血糖监测，避免低血糖发生。",
          "start_idx": 0,
          "end_idx": 50,
          "entities": [
            {
              "entity_id": "T394",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 5,
              "end_idx": 8
            },
            {
              "entity_id": "T395",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 9,
              "end_idx": 14
            },
            {
              "entity_id": "T396",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 23,
              "end_idx": 26
            },
            {
              "entity_id": "T397",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 27,
              "end_idx": 32
            },
            {
              "entity_id": "T398",
              "entity": "血糖监测",
              "entity_type": "Test_items",
              "start_idx": 37,
              "end_idx": 41
            },
            {
              "entity_id": "T399",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 44,
              "end_idx": 47
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R131",
              "head_entity_id": "T399",
              "tail_entity_id": "T394"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R132",
              "head_entity_id": "T399",
              "tail_entity_id": "T395"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R133",
              "head_entity_id": "T399",
              "tail_entity_id": "T396"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R134",
              "head_entity_id": "T399",
              "tail_entity_id": "T397"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "68",
      "paragraph": "C.DKA SGLT-2抑制剂在上市前研究和上市后应用过程中，都有过糖尿病酮症酸中毒(DKA)及酮症的病例报告，但非常少见。发生者大多存在手术、过度运动、心肌梗死、卒中、严重感染、长时间禁食或极低碳水化合物摄入量和其他生理及病理应激等诱因，部分联用胰岛素的患者胰岛素减量过快。使用此类药物发生DKA及酮症的患者症状不典型，血糖通常不超过13.9毫摩尔/升，被称为“血糖不高的DKA”，往往不易被诊断。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "C.DKA SGLT-2抑制剂在上市前研究和上市后应用过程中，都有过糖尿病酮症酸中毒(DKA)及酮症的病例报告，但非常少见。发生者大多存在手术、过度运动、心肌梗死、卒中、严重感染、长时间禁食或极低碳水化合物摄入量和其他生理及病理应激等诱因，部分联用胰岛素的患者胰岛素减量过快。使用此类药物发生DKA及酮症的患者症状不典型，血糖通常不超过13.9毫摩尔/升，被称为“血糖不高的DKA”，往往不易被诊断。",
          "start_idx": 0,
          "end_idx": 200,
          "entities": [
            {
              "entity_id": "T400",
              "entity": "SGLT-2抑制剂",
              "entity_type": "Drug",
              "start_idx": 6,
              "end_idx": 15
            },
            {
              "entity_id": "T401",
              "entity": "DKA",
              "entity_type": "Disease",
              "start_idx": 2,
              "end_idx": 5
            },
            {
              "entity_id": "T402",
              "entity": "糖尿病酮症酸中毒(DKA)",
              "entity_type": "Disease",
              "start_idx": 34,
              "end_idx": 47
            },
            {
              "entity_id": "T403",
              "entity": "酮症",
              "entity_type": "Disease",
              "start_idx": 48,
              "end_idx": 50
            },
            {
              "entity_id": "T404",
              "entity": "DKA",
              "entity_type": "Disease",
              "start_idx": 146,
              "end_idx": 149
            },
            {
              "entity_id": "T405",
              "entity": "酮症",
              "entity_type": "Disease",
              "start_idx": 150,
              "end_idx": 152
            },
            {
              "entity_id": "T406",
              "entity": "DKA",
              "entity_type": "Disease",
              "start_idx": 187,
              "end_idx": 190
            },
            {
              "entity_id": "T407",
              "entity": "手术",
              "entity_type": "Reason",
              "start_idx": 69,
              "end_idx": 71
            },
            {
              "entity_id": "T408",
              "entity": "过度运动",
              "entity_type": "Reason",
              "start_idx": 72,
              "end_idx": 76
            },
            {
              "entity_id": "T409",
              "entity": "心肌梗死",
              "entity_type": "Reason",
              "start_idx": 77,
              "end_idx": 81
            },
            {
              "entity_id": "T410",
              "entity": "卒中",
              "entity_type": "Reason",
              "start_idx": 82,
              "end_idx": 84
            },
            {
              "entity_id": "T411",
              "entity": "严重感染",
              "entity_type": "Reason",
              "start_idx": 85,
              "end_idx": 89
            },
            {
              "entity_id": "T412",
              "entity": "长时间禁食",
              "entity_type": "Reason",
              "start_idx": 90,
              "end_idx": 95
            },
            {
              "entity_id": "T413",
              "entity": "极低碳水化合物摄入量",
              "entity_type": "Reason",
              "start_idx": 96,
              "end_idx": 106
            },
            {
              "entity_id": "T414",
              "entity": "其他生理及病理应激",
              "entity_type": "Reason",
              "start_idx": 107,
              "end_idx": 116
            },
            {
              "entity_id": "T415",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 124,
              "end_idx": 127
            },
            {
              "entity_id": "T416",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 130,
              "end_idx": 133
            },
            {
              "entity_id": "T417",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 161,
              "end_idx": 163
            },
            {
              "entity_id": "T418",
              "entity": "不超过13.9毫摩尔/升",
              "entity_type": "Test_Value",
              "start_idx": 165,
              "end_idx": 177
            },
            {
              "entity_id": "T419",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 182,
              "end_idx": 184
            },
            {
              "entity_id": "T420",
              "entity": "不高",
              "entity_type": "Test_Value",
              "start_idx": 184,
              "end_idx": 186
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R135",
              "head_entity_id": "T419",
              "tail_entity_id": "T406"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "69",
      "paragraph": "【应对】用药期间，如出现和DKA相关的症状，如腹痛、恶心、呕吐、乏力、呼吸困难，需要考虑是否出现DKA并检测血酮和动脉血酸碱度以明确诊断。明确诊断为DKA者，应立即停用SGLT-2抑制剂，并按照传统DKA治疗程序进行治疗。为减少用药期间发生DKA的风险，建议在择期手术、剧烈体力活动(如马拉松)前24小时停用SGLT-2抑制剂，同时注意停药后的后续效应；避免停用胰岛素或过度减量；对于紧急手术或大的应激状态，需立即停用SGLT-2抑制剂，采用其他合适降糖措施；口服SGLT2抑制剂期间避免过多饮酒及极低碳水化合物饮食。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "【应对】用药期间，如出现和DKA相关的症状，如腹痛、恶心、呕吐、乏力、呼吸困难，需要考虑是否出现DKA并检测血酮和动脉血酸碱度以明确诊断。明确诊断为DKA者，应立即停用SGLT-2抑制剂，并按照传统DKA治疗程序进行治疗。为减少用药期间发生DKA的风险，建议在择期手术、剧烈体力活动(如马拉松)前24小时停用SGLT-2抑制剂，同时注意停药后的后续效应；避免停用胰岛素或过度减量；对于紧急手术或大的应激状态，需立即停用SGLT-2抑制剂，采用其他合适降糖措施；口服SGLT2抑制剂期间避免过多饮酒及极低碳水化合物饮食。",
          "start_idx": 0,
          "end_idx": 259,
          "entities": [
            {
              "entity_id": "T421",
              "entity": "DKA",
              "entity_type": "Disease",
              "start_idx": 13,
              "end_idx": 16
            },
            {
              "entity_id": "T422",
              "entity": "DKA",
              "entity_type": "Disease",
              "start_idx": 48,
              "end_idx": 51
            },
            {
              "entity_id": "T423",
              "entity": "DKA",
              "entity_type": "Disease",
              "start_idx": 74,
              "end_idx": 77
            },
            {
              "entity_id": "T424",
              "entity": "DKA",
              "entity_type": "Disease",
              "start_idx": 99,
              "end_idx": 102
            },
            {
              "entity_id": "T425",
              "entity": "DKA",
              "entity_type": "Disease",
              "start_idx": 120,
              "end_idx": 123
            },
            {
              "entity_id": "T426",
              "entity": "腹痛",
              "entity_type": "Symptom",
              "start_idx": 23,
              "end_idx": 25
            },
            {
              "entity_id": "T427",
              "entity": "恶心",
              "entity_type": "Symptom",
              "start_idx": 26,
              "end_idx": 28
            },
            {
              "entity_id": "T428",
              "entity": "呕吐",
              "entity_type": "Symptom",
              "start_idx": 29,
              "end_idx": 31
            },
            {
              "entity_id": "T429",
              "entity": "乏力",
              "entity_type": "Symptom",
              "start_idx": 32,
              "end_idx": 34
            },
            {
              "entity_id": "T430",
              "entity": "呼吸困难",
              "entity_type": "Symptom",
              "start_idx": 35,
              "end_idx": 39
            },
            {
              "entity_id": "T431",
              "entity": "血酮",
              "entity_type": "Test_items",
              "start_idx": 54,
              "end_idx": 56
            },
            {
              "entity_id": "T432",
              "entity": "动脉血酸碱度",
              "entity_type": "Test_items",
              "start_idx": 57,
              "end_idx": 63
            },
            {
              "entity_id": "T433",
              "entity": "SGLT-2抑制剂",
              "entity_type": "Drug",
              "start_idx": 84,
              "end_idx": 93
            },
            {
              "entity_id": "T434",
              "entity": "SGLT-2抑制剂",
              "entity_type": "Drug",
              "start_idx": 154,
              "end_idx": 163
            },
            {
              "entity_id": "T435",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 181,
              "end_idx": 184
            },
            {
              "entity_id": "T436",
              "entity": "SGLT-2抑制剂",
              "entity_type": "Drug",
              "start_idx": 209,
              "end_idx": 218
            },
            {
              "entity_id": "T437",
              "entity": "SGLT2抑制剂",
              "entity_type": "Drug",
              "start_idx": 232,
              "end_idx": 240
            },
            {
              "entity_id": "T438",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 230,
              "end_idx": 232
            }
          ],
          "relations": [
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R136",
              "head_entity_id": "T426",
              "tail_entity_id": "T421"
            },
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R137",
              "head_entity_id": "T427",
              "tail_entity_id": "T421"
            },
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R138",
              "head_entity_id": "T428",
              "tail_entity_id": "T421"
            },
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R139",
              "head_entity_id": "T429",
              "tail_entity_id": "T421"
            },
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R140",
              "head_entity_id": "T430",
              "tail_entity_id": "T421"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R141",
              "head_entity_id": "T431",
              "tail_entity_id": "T422"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R142",
              "head_entity_id": "T432",
              "tail_entity_id": "T422"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R143",
              "head_entity_id": "T438",
              "tail_entity_id": "T437"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "70",
      "paragraph": "特殊情况",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "特殊情况",
          "start_idx": 0,
          "end_idx": 4,
          "entities": [],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "71",
      "paragraph": "(1)老年",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(1)老年",
          "start_idx": 0,
          "end_idx": 5,
          "entities": [],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "72",
      "paragraph": "老年患者在原有治疗方案疗效不佳时加用SGLT-2抑制剂，可有效降低血糖、减轻体重和降低血压，且耐受性良好。不过，老年患者需监测肾功能，肾功能正常或轻度不全时可使用。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "老年患者在原有治疗方案疗效不佳时加用SGLT-2抑制剂，可有效降低血糖、减轻体重和降低血压，且耐受性良好。",
          "start_idx": 0,
          "end_idx": 53,
          "entities": [
            {
              "entity_id": "T439",
              "entity": "SGLT-2抑制剂",
              "entity_type": "Drug",
              "start_idx": 18,
              "end_idx": 27
            },
            {
              "entity_id": "T441",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 33,
              "end_idx": 35
            },
            {
              "entity_id": "T442",
              "entity": "血压",
              "entity_type": "Test",
              "start_idx": 43,
              "end_idx": 45
            }
          ],
          "relations": []
        },
        {
          "sentence_id": "1",
          "sentence": "不过，老年患者需监测肾功能，肾功能正常或轻度不全时可使用。",
          "start_idx": 53,
          "end_idx": 82,
          "entities": [
            {
              "entity_id": "T440",
              "entity": "监测肾功能",
              "entity_type": "Test",
              "start_idx": 8,
              "end_idx": 13
            },
            {
              "entity_id": "T443",
              "entity": "轻度",
              "entity_type": "Level",
              "start_idx": 20,
              "end_idx": 22
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "74",
      "paragraph": "SGLT-2抑制剂在中度肾功能不全患者可减量使用，起始治疗前需检测肾功能，根据肾功能确认是否可以起始，治疗中每年至少监测一次肾功能，如同时予以影响肾功能的药物，起始前也需监测肾功能，当肾功能逐渐下降并趋向于中度肾功能不全时，则需每年监测2~4次肾功能。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "SGLT-2抑制剂在中度肾功能不全患者可减量使用，起始治疗前需检测肾功能，根据肾功能确认是否可以起始，治疗中每年至少监测一次肾功能，如同时予以影响肾功能的药物，起始前也需监测肾功能，当肾功能逐渐下降并趋向于中度肾功能不全时，则需每年监测2~4次肾功能。",
          "start_idx": 0,
          "end_idx": 126,
          "entities": [
            {
              "entity_id": "T444",
              "entity": "SGLT-2抑制剂",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 9
            },
            {
              "entity_id": "T445",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 12,
              "end_idx": 17
            },
            {
              "entity_id": "T446",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 12,
              "end_idx": 13
            },
            {
              "entity_id": "T447",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 105,
              "end_idx": 110
            },
            {
              "entity_id": "T448",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 105,
              "end_idx": 106
            },
            {
              "entity_id": "T449",
              "entity": "中度",
              "entity_type": "Level",
              "start_idx": 10,
              "end_idx": 12
            },
            {
              "entity_id": "T450",
              "entity": "中度",
              "entity_type": "Level",
              "start_idx": 103,
              "end_idx": 105
            },
            {
              "entity_id": "T451",
              "entity": "检测肾功能",
              "entity_type": "Test",
              "start_idx": 31,
              "end_idx": 36
            },
            {
              "entity_id": "T452",
              "entity": "监测一次肾功能",
              "entity_type": "Test",
              "start_idx": 58,
              "end_idx": 65
            },
            {
              "entity_id": "T453",
              "entity": "监测肾功能",
              "entity_type": "Test",
              "start_idx": 85,
              "end_idx": 90
            },
            {
              "entity_id": "T454",
              "entity": "监测2~4次肾功能",
              "entity_type": "Test",
              "start_idx": 116,
              "end_idx": 125
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R144",
              "head_entity_id": "T444",
              "tail_entity_id": "T445"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R145",
              "head_entity_id": "T446",
              "tail_entity_id": "T445"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R146",
              "head_entity_id": "T451",
              "tail_entity_id": "T445"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R147",
              "head_entity_id": "T448",
              "tail_entity_id": "T447"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R148",
              "head_entity_id": "T454",
              "tail_entity_id": "T447"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "75",
      "paragraph": "SGLT-2抑制剂在轻中度肝功能不全时也可使用。由于在重度肝功能不全的2型糖尿病患者中使用数据有限。欧美国家的药物说明书中均不推荐用于重度肝功能不全患者。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "SGLT-2抑制剂在轻中度肝功能不全时也可使用。由于在重度肝功能不全的2型糖尿病患者中使用数据有限。欧美国家的药物说明书中均不推荐用于重度肝功能不全患者。",
          "start_idx": 0,
          "end_idx": 77,
          "entities": [
            {
              "entity_id": "T455",
              "entity": "SGLT-2抑制剂",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 9
            },
            {
              "entity_id": "T456",
              "entity": "肝功能不全",
              "entity_type": "Disease",
              "start_idx": 13,
              "end_idx": 18
            },
            {
              "entity_id": "T457",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 13,
              "end_idx": 14
            },
            {
              "entity_id": "T458",
              "entity": "肝功能不全",
              "entity_type": "Disease",
              "start_idx": 29,
              "end_idx": 34
            },
            {
              "entity_id": "T459",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 35,
              "end_idx": 40
            },
            {
              "entity_id": "T460",
              "entity": "肝功能不全",
              "entity_type": "Disease",
              "start_idx": 69,
              "end_idx": 74
            },
            {
              "entity_id": "T461",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 29,
              "end_idx": 30
            },
            {
              "entity_id": "T462",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 69,
              "end_idx": 70
            },
            {
              "entity_id": "T463",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 35,
              "end_idx": 37
            },
            {
              "entity_id": "T464",
              "entity": "轻中度",
              "entity_type": "Level",
              "start_idx": 10,
              "end_idx": 13
            },
            {
              "entity_id": "T465",
              "entity": "重度",
              "entity_type": "Level",
              "start_idx": 27,
              "end_idx": 29
            },
            {
              "entity_id": "T466",
              "entity": "重度",
              "entity_type": "Level",
              "start_idx": 67,
              "end_idx": 69
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R149",
              "head_entity_id": "T455",
              "tail_entity_id": "T456"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R150",
              "head_entity_id": "T457",
              "tail_entity_id": "T456"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R151",
              "head_entity_id": "T461",
              "tail_entity_id": "T458"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R152",
              "head_entity_id": "T463",
              "tail_entity_id": "T459"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R153",
              "head_entity_id": "T462",
              "tail_entity_id": "T460"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "76",
      "paragraph": "(3)心血管疾病",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(3)心血管疾病",
          "start_idx": 0,
          "end_idx": 8,
          "entities": [
            {
              "entity_id": "T467",
              "entity": "心血管疾病",
              "entity_type": "Disease",
              "start_idx": 3,
              "end_idx": 8
            },
            {
              "entity_id": "T468",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 3,
              "end_idx": 6
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R154",
              "head_entity_id": "T468",
              "tail_entity_id": "T467"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "77",
      "paragraph": "SGLT-2抑制剂除有效降糖外。还具有减重、降压、降尿酸、减少蛋白尿等与心血管疾病相关危险因素的作用，目前也有一些研究证实此类药物确实能够降低心血管事件风险。不过，由于此类药物刚刚进入中国，我们还需要更多的临床数据去了解它们。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "SGLT-2抑制剂除有效降糖外。",
          "start_idx": 0,
          "end_idx": 16,
          "entities": [
            {
              "entity_id": "T469",
              "entity": "SGLT-2抑制剂",
              "entity_type": "Disease",
              "start_idx": 0,
              "end_idx": 9
            }
          ],
          "relations": []
        },
        {
          "sentence_id": "1",
          "sentence": "还具有减重、降压、降尿酸、减少蛋白尿等与心血管疾病相关危险因素的作用，目前也有一些研究证实此类药物确实能够降低心血管事件风险。",
          "start_idx": 16,
          "end_idx": 79,
          "entities": [
            {
              "entity_id": "T470",
              "entity": "心血管疾病",
              "entity_type": "Disease",
              "start_idx": 20,
              "end_idx": 25
            },
            {
              "entity_id": "T471",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 20,
              "end_idx": 23
            },
            {
              "entity_id": "T472",
              "entity": "心血管事件",
              "entity_type": "Disease",
              "start_idx": 55,
              "end_idx": 60
            },
            {
              "entity_id": "T473",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 55,
              "end_idx": 58
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R155",
              "head_entity_id": "T471",
              "tail_entity_id": "T470"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R156",
              "head_entity_id": "T473",
              "tail_entity_id": "T472"
            }
          ]
        },
        {
          "sentence_id": "2",
          "sentence": "不过，由于此类药物刚刚进入中国，我们还需要更多的临床数据去了解它们。",
          "start_idx": 79,
          "end_idx": 113,
          "entities": [],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "78",
      "paragraph": "(4)其他",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(4)其他",
          "start_idx": 0,
          "end_idx": 5,
          "entities": [],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "79",
      "paragraph": "目前，临床研究数据尚未证实此类药物与膀胱癌风险存在因果关系，上市后至今尚无相关肿瘤病例报告；FDA和EMA根据不良事件报告系统的数据，已加强提醒在使用SGLT-2抑制剂过程中，注意骨折风险(坎格列净)、足趾截肢风险(坎格列净)及急性肾损伤风险(达格列净、坎格列净)，但它们之间是否存在因果关系仍需要进一步研究。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "目前，临床研究数据尚未证实此类药物与膀胱癌风险存在因果关系，上市后至今尚无相关肿瘤病例报告；FDA和EMA根据不良事件报告系统的数据，已加强提醒在使用SGLT-2抑制剂过程中，注意骨折风险(坎格列净)、足趾截肢风险(坎格列净)及急性肾损伤风险(达格列净、坎格列净)，但它们之间是否存在因果关系仍需要进一步研究。",
          "start_idx": 0,
          "end_idx": 155,
          "entities": [
            {
              "entity_id": "T474",
              "entity": "膀胱癌",
              "entity_type": "Disease",
              "start_idx": 18,
              "end_idx": 21
            },
            {
              "entity_id": "T475",
              "entity": "膀胱",
              "entity_type": "Anatomy",
              "start_idx": 18,
              "end_idx": 20
            },
            {
              "entity_id": "T476",
              "entity": "肿瘤",
              "entity_type": "Disease",
              "start_idx": 39,
              "end_idx": 41
            },
            {
              "entity_id": "T477",
              "entity": "SGLT-2抑制剂",
              "entity_type": "Drug",
              "start_idx": 75,
              "end_idx": 84
            },
            {
              "entity_id": "T478",
              "entity": "骨折",
              "entity_type": "Disease",
              "start_idx": 90,
              "end_idx": 92
            },
            {
              "entity_id": "T479",
              "entity": "足趾截肢",
              "entity_type": "Disease",
              "start_idx": 101,
              "end_idx": 105
            },
            {
              "entity_id": "T480",
              "entity": "足趾",
              "entity_type": "Anatomy",
              "start_idx": 101,
              "end_idx": 103
            },
            {
              "entity_id": "T481",
              "entity": "急性肾损伤",
              "entity_type": "Disease",
              "start_idx": 114,
              "end_idx": 119
            },
            {
              "entity_id": "T482",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 116,
              "end_idx": 117
            },
            {
              "entity_id": "T483",
              "entity": "达格列净",
              "entity_type": "Drug",
              "start_idx": 122,
              "end_idx": 126
            },
            {
              "entity_id": "T484",
              "entity": "坎格列净",
              "entity_type": "Drug",
              "start_idx": 127,
              "end_idx": 131
            },
            {
              "entity_id": "T485",
              "entity": "坎格列净",
              "entity_type": "Drug",
              "start_idx": 95,
              "end_idx": 99
            },
            {
              "entity_id": "T486",
              "entity": "坎格列净",
              "entity_type": "Drug",
              "start_idx": 108,
              "end_idx": 112
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R157",
              "head_entity_id": "T475",
              "tail_entity_id": "T474"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R158",
              "head_entity_id": "T477",
              "tail_entity_id": "T476"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R159",
              "head_entity_id": "T480",
              "tail_entity_id": "T479"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R160",
              "head_entity_id": "T482",
              "tail_entity_id": "T481"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "73",
      "paragraph": "(2)肝肾功能不全",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(2)肝肾功能不全",
          "start_idx": 0,
          "end_idx": 9,
          "entities": [
            {
              "entity_id": "T487",
              "entity": "肝肾功能不全",
              "entity_type": "Disease",
              "start_idx": 3,
              "end_idx": 9
            },
            {
              "entity_id": "T488",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 3,
              "end_idx": 4
            },
            {
              "entity_id": "T489",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 4,
              "end_idx": 5
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R161",
              "head_entity_id": "T489",
              "tail_entity_id": "T487"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R162",
              "head_entity_id": "T488",
              "tail_entity_id": "T487"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "59",
      "paragraph": "由于中国建议发布时，此类药物尚未在国内上市，所以仅介绍了国外的使用情况，美国药品食品监督管理局(FDA)批准达格列净和恩格列净的起始剂量分别为5毫克和10毫克，根据血糖控制的需求和是否耐受可调整至最大剂量10毫克和25毫克，每日一次口服。与FDA不同的是，欧洲药物机构(EMA)推荐达格列净的起始剂量为10毫克，对于重度肝功能不全的患者可从5毫克起始。美国临床内分泌医师协会(AACE)、美国糖尿病学会和欧洲糖尿病学会(ADA/EASD)指南推荐SGLT一2抑制剂可单独使用及与其他降糖药物联合使用。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "由于中国建议发布时，此类药物尚未在国内上市，所以仅介绍了国外的使用情况，美国药品食品监督管理局(FDA)批准达格列净和恩格列净的起始剂量分别为5毫克和10毫克，根据血糖控制的需求和是否耐受可调整至最大剂量10毫克和25毫克，每日一次口服。与FDA不同的是，欧洲药物机构(EMA)推荐达格列净的起始剂量为10毫克，对于重度肝功能不全的患者可从5毫克起始。",
          "start_idx": 0,
          "end_idx": 176,
          "entities": [
            {
              "entity_id": "T490",
              "entity": "达格列净",
              "entity_type": "Drug",
              "start_idx": 54,
              "end_idx": 58
            },
            {
              "entity_id": "T491",
              "entity": "恩格列净",
              "entity_type": "Drug",
              "start_idx": 59,
              "end_idx": 63
            },
            {
              "entity_id": "T492",
              "entity": "达格列净",
              "entity_type": "Drug",
              "start_idx": 141,
              "end_idx": 145
            },
            {
              "entity_id": "T494",
              "entity": "5毫克",
              "entity_type": "Amount",
              "start_idx": 71,
              "end_idx": 74
            },
            {
              "entity_id": "T495",
              "entity": "10毫克",
              "entity_type": "Amount",
              "start_idx": 75,
              "end_idx": 79
            },
            {
              "entity_id": "T496",
              "entity": "10毫克",
              "entity_type": "Amount",
              "start_idx": 102,
              "end_idx": 106
            },
            {
              "entity_id": "T497",
              "entity": "25毫克",
              "entity_type": "Amount",
              "start_idx": 107,
              "end_idx": 111
            },
            {
              "entity_id": "T498",
              "entity": "10毫克",
              "entity_type": "Amount",
              "start_idx": 151,
              "end_idx": 155
            },
            {
              "entity_id": "T499",
              "entity": "5毫克",
              "entity_type": "Amount",
              "start_idx": 170,
              "end_idx": 173
            },
            {
              "entity_id": "T500",
              "entity": "每日一次",
              "entity_type": "Frequency",
              "start_idx": 112,
              "end_idx": 116
            },
            {
              "entity_id": "T501",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 116,
              "end_idx": 118
            },
            {
              "entity_id": "T502",
              "entity": "肝功能不全",
              "entity_type": "Disease",
              "start_idx": 160,
              "end_idx": 165
            },
            {
              "entity_id": "T503",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 160,
              "end_idx": 161
            },
            {
              "entity_id": "T504",
              "entity": "重度",
              "entity_type": "Level",
              "start_idx": 158,
              "end_idx": 160
            },
            {
              "entity_id": "T505",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 82,
              "end_idx": 84
            }
          ],
          "relations": [
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R163",
              "head_entity_id": "T494",
              "tail_entity_id": "T490"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R164",
              "head_entity_id": "T496",
              "tail_entity_id": "T490"
            },
            {
              "relation_type": "Frequency_Drug",
              "relation_id": "R165",
              "head_entity_id": "T500",
              "tail_entity_id": "T490"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R166",
              "head_entity_id": "T501",
              "tail_entity_id": "T490"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R167",
              "head_entity_id": "T495",
              "tail_entity_id": "T491"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R168",
              "head_entity_id": "T497",
              "tail_entity_id": "T491"
            },
            {
              "relation_type": "Frequency_Drug",
              "relation_id": "R169",
              "head_entity_id": "T500",
              "tail_entity_id": "T491"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R170",
              "head_entity_id": "T501",
              "tail_entity_id": "T491"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R171",
              "head_entity_id": "T498",
              "tail_entity_id": "T492"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R172",
              "head_entity_id": "T499",
              "tail_entity_id": "T492"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R173",
              "head_entity_id": "T492",
              "tail_entity_id": "T502"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R174",
              "head_entity_id": "T503",
              "tail_entity_id": "T502"
            }
          ]
        },
        {
          "sentence_id": "1",
          "sentence": "美国临床内分泌医师协会(AACE)、美国糖尿病学会和欧洲糖尿病学会(ADA/EASD)指南推荐SGLT一2抑制剂可单独使用及与其他降糖药物联合使用。",
          "start_idx": 176,
          "end_idx": 250,
          "entities": [
            {
              "entity_id": "T493",
              "entity": "SGLT一2抑制剂",
              "entity_type": "Drug",
              "start_idx": 47,
              "end_idx": 56
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "19",
      "paragraph": "快速建议指南推荐DPP-4抑制剂联合基础胰岛用于2型糖尿病患者的降糖治疗，指出当使用基础胰岛素进行治疗，糖化血红蛋白水平仍控制不佳时，添加DPP-4抑制剂进行联合治疗，并根据糖化血红白水平，调整胰岛素的剂量。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "快速建议指南推荐DPP-4抑制剂联合基础胰岛用于2型糖尿病患者的降糖治疗，指出当使用基础胰岛素进行治疗，糖化血红蛋白水平仍控制不佳时，添加DPP-4抑制剂进行联合治疗，并根据糖化血红白水平，调整胰岛素的剂量。",
          "start_idx": 0,
          "end_idx": 104,
          "entities": [
            {
              "entity_id": "T506",
              "entity": "DPP-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 8,
              "end_idx": 16
            },
            {
              "entity_id": "T507",
              "entity": "基础胰岛",
              "entity_type": "Drug",
              "start_idx": 18,
              "end_idx": 22
            },
            {
              "entity_id": "T508",
              "entity": "基础胰岛素",
              "entity_type": "Drug",
              "start_idx": 42,
              "end_idx": 47
            },
            {
              "entity_id": "T509",
              "entity": "DPP-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 69,
              "end_idx": 77
            },
            {
              "entity_id": "T510",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 97,
              "end_idx": 100
            },
            {
              "entity_id": "T511",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 24,
              "end_idx": 29
            },
            {
              "entity_id": "T512",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 24,
              "end_idx": 26
            },
            {
              "entity_id": "T513",
              "entity": "糖化血红蛋白",
              "entity_type": "Test_items",
              "start_idx": 52,
              "end_idx": 58
            },
            {
              "entity_id": "T514",
              "entity": "控制不佳",
              "entity_type": "Test_Value",
              "start_idx": 61,
              "end_idx": 65
            },
            {
              "entity_id": "T515",
              "entity": "糖化血红白",
              "entity_type": "Test_items",
              "start_idx": 87,
              "end_idx": 92
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R175",
              "head_entity_id": "T506",
              "tail_entity_id": "T511"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R176",
              "head_entity_id": "T507",
              "tail_entity_id": "T511"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R177",
              "head_entity_id": "T512",
              "tail_entity_id": "T511"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R178",
              "head_entity_id": "T513",
              "tail_entity_id": "T511"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R179",
              "head_entity_id": "T515",
              "tail_entity_id": "T511"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "16",
      "paragraph": "B.肝功能不全：西格列汀用于轻度或中度肝功能不全的患者，不需要进行剂量调整，尚无严重肝功能不全患者使用的临床经验；维格列汀不推荐用于开始给药前血清谷丙转氨酶或谷草转氨酶大于正常上限3倍的患者，罕见有肝功能障碍(包括肝炎)报告，但需要定期检测肝酶，对用药中发生肝酶异常者，在肝功能检测恢复正常后，不建议重新使用；沙格列汀用于中度肝功能不全的患者时需谨慎，不推荐用于重度肝功能不全的患者；利格列汀在不同程度肝功能不全的患者中使用，均不需要调整剂量；阿格列汀在肝功能检查结果异常的患者中应慎重使用，如患者报告发生可能提示肝损伤的症状，应迅速进行肝功能检查，出现具有临床意义的肝酶升高或肝功能检查异常结果持续或恶化时，应停用，如未发现引起肝功能检查异常的其他原因，则不要再次使用。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "B.肝功能不全：西格列汀用于轻度或中度肝功能不全的患者，不需要进行剂量调整，尚无严重肝功能不全患者使用的临床经验；维格列汀不推荐用于开始给药前血清谷丙转氨酶或谷草转氨酶大于正常上限3倍的患者，罕见有肝功能障碍(包括肝炎)报告，但需要定期检测肝酶，对用药中发生肝酶异常者，在肝功能检测恢复正常后，不建议重新使用；沙格列汀用于中度肝功能不全的患者时需谨慎，不推荐用于重度肝功能不全的患者；利格列汀在不同程度肝功能不全的患者中使用，均不需要调整剂量；阿格列汀在肝功能检查结果异常的患者中应慎重使用，如患者报告发生可能提示肝损伤的症状，应迅速进行肝功能检查，出现具有临床意义的肝酶升高或肝功能检查异常结果持续或恶化时，应停用，如未发现引起肝功能检查异常的其他原因，则不要再次使用。",
          "start_idx": 0,
          "end_idx": 336,
          "entities": [
            {
              "entity_id": "T516",
              "entity": "肝功能不全",
              "entity_type": "Disease",
              "start_idx": 2,
              "end_idx": 7
            },
            {
              "entity_id": "T517",
              "entity": "肝功能不全",
              "entity_type": "Disease",
              "start_idx": 19,
              "end_idx": 24
            },
            {
              "entity_id": "T518",
              "entity": "肝功能不全",
              "entity_type": "Disease",
              "start_idx": 42,
              "end_idx": 47
            },
            {
              "entity_id": "T519",
              "entity": "肝功能障碍",
              "entity_type": "Disease",
              "start_idx": 99,
              "end_idx": 104
            },
            {
              "entity_id": "T520",
              "entity": "肝炎",
              "entity_type": "Disease",
              "start_idx": 107,
              "end_idx": 109
            },
            {
              "entity_id": "T521",
              "entity": "肝功能不全",
              "entity_type": "Disease",
              "start_idx": 163,
              "end_idx": 168
            },
            {
              "entity_id": "T522",
              "entity": "肝功能不全",
              "entity_type": "Disease",
              "start_idx": 183,
              "end_idx": 188
            },
            {
              "entity_id": "T523",
              "entity": "肝功能不全",
              "entity_type": "Disease",
              "start_idx": 201,
              "end_idx": 206
            },
            {
              "entity_id": "T524",
              "entity": "肝损伤",
              "entity_type": "Disease",
              "start_idx": 257,
              "end_idx": 260
            },
            {
              "entity_id": "T525",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 2,
              "end_idx": 3
            },
            {
              "entity_id": "T526",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 19,
              "end_idx": 20
            },
            {
              "entity_id": "T527",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 42,
              "end_idx": 43
            },
            {
              "entity_id": "T528",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 99,
              "end_idx": 100
            },
            {
              "entity_id": "T529",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 107,
              "end_idx": 108
            },
            {
              "entity_id": "T530",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 163,
              "end_idx": 164
            },
            {
              "entity_id": "T531",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 183,
              "end_idx": 184
            },
            {
              "entity_id": "T532",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 201,
              "end_idx": 202
            },
            {
              "entity_id": "T533",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 257,
              "end_idx": 258
            },
            {
              "entity_id": "T534",
              "entity": "西格列汀",
              "entity_type": "Drug",
              "start_idx": 8,
              "end_idx": 12
            },
            {
              "entity_id": "T535",
              "entity": "维格列汀",
              "entity_type": "Drug",
              "start_idx": 57,
              "end_idx": 61
            },
            {
              "entity_id": "T536",
              "entity": "沙格列汀",
              "entity_type": "Drug",
              "start_idx": 155,
              "end_idx": 159
            },
            {
              "entity_id": "T537",
              "entity": "利格列汀",
              "entity_type": "Drug",
              "start_idx": 192,
              "end_idx": 196
            },
            {
              "entity_id": "T538",
              "entity": "阿格列汀",
              "entity_type": "Drug",
              "start_idx": 222,
              "end_idx": 226
            },
            {
              "entity_id": "T539",
              "entity": "轻度",
              "entity_type": "Level",
              "start_idx": 14,
              "end_idx": 16
            },
            {
              "entity_id": "T540",
              "entity": "中度",
              "entity_type": "Level",
              "start_idx": 17,
              "end_idx": 19
            },
            {
              "entity_id": "T541",
              "entity": "严重",
              "entity_type": "Level",
              "start_idx": 40,
              "end_idx": 42
            },
            {
              "entity_id": "T542",
              "entity": "中度",
              "entity_type": "Level",
              "start_idx": 161,
              "end_idx": 163
            },
            {
              "entity_id": "T543",
              "entity": "重度",
              "entity_type": "Level",
              "start_idx": 181,
              "end_idx": 183
            },
            {
              "entity_id": "T544",
              "entity": "血清谷丙转氨酶",
              "entity_type": "Test_items",
              "start_idx": 71,
              "end_idx": 78
            },
            {
              "entity_id": "T545",
              "entity": "谷草转氨酶",
              "entity_type": "Test_items",
              "start_idx": 79,
              "end_idx": 84
            },
            {
              "entity_id": "T546",
              "entity": "肝酶",
              "entity_type": "Test_items",
              "start_idx": 120,
              "end_idx": 122
            },
            {
              "entity_id": "T547",
              "entity": "肝酶",
              "entity_type": "Test_items",
              "start_idx": 129,
              "end_idx": 131
            },
            {
              "entity_id": "T548",
              "entity": "肝酶",
              "entity_type": "Test_items",
              "start_idx": 284,
              "end_idx": 286
            },
            {
              "entity_id": "T549",
              "entity": "大于正常上限3倍",
              "entity_type": "Test_Value",
              "start_idx": 84,
              "end_idx": 92
            },
            {
              "entity_id": "T550",
              "entity": "异常",
              "entity_type": "Test_Value",
              "start_idx": 131,
              "end_idx": 133
            },
            {
              "entity_id": "T551",
              "entity": "肝功能检测",
              "entity_type": "Test",
              "start_idx": 136,
              "end_idx": 141
            },
            {
              "entity_id": "T552",
              "entity": "肝功能检查",
              "entity_type": "Test",
              "start_idx": 227,
              "end_idx": 232
            },
            {
              "entity_id": "T553",
              "entity": "肝功能检查",
              "entity_type": "Test",
              "start_idx": 269,
              "end_idx": 274
            },
            {
              "entity_id": "T554",
              "entity": "肝功能检查",
              "entity_type": "Test",
              "start_idx": 289,
              "end_idx": 294
            },
            {
              "entity_id": "T555",
              "entity": "肝功能检查",
              "entity_type": "Test",
              "start_idx": 315,
              "end_idx": 320
            },
            {
              "entity_id": "T556",
              "entity": "升高",
              "entity_type": "Test_Value",
              "start_idx": 286,
              "end_idx": 288
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R180",
              "head_entity_id": "T525",
              "tail_entity_id": "T516"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R181",
              "head_entity_id": "T534",
              "tail_entity_id": "T516"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R182",
              "head_entity_id": "T526",
              "tail_entity_id": "T517"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R183",
              "head_entity_id": "T534",
              "tail_entity_id": "T517"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R184",
              "head_entity_id": "T527",
              "tail_entity_id": "T518"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R185",
              "head_entity_id": "T528",
              "tail_entity_id": "T519"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R186",
              "head_entity_id": "T535",
              "tail_entity_id": "T519"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R187",
              "head_entity_id": "T546",
              "tail_entity_id": "T519"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R188",
              "head_entity_id": "T547",
              "tail_entity_id": "T519"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R189",
              "head_entity_id": "T529",
              "tail_entity_id": "T520"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R190",
              "head_entity_id": "T535",
              "tail_entity_id": "T520"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R191",
              "head_entity_id": "T546",
              "tail_entity_id": "T520"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R192",
              "head_entity_id": "T547",
              "tail_entity_id": "T520"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R193",
              "head_entity_id": "T530",
              "tail_entity_id": "T521"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R194",
              "head_entity_id": "T536",
              "tail_entity_id": "T521"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R195",
              "head_entity_id": "T531",
              "tail_entity_id": "T522"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R196",
              "head_entity_id": "T532",
              "tail_entity_id": "T523"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R197",
              "head_entity_id": "T533",
              "tail_entity_id": "T524"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R198",
              "head_entity_id": "T553",
              "tail_entity_id": "T524"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "15",
      "paragraph": "A.肾功能不全：西格列汀通过肾脏代谢，用于中、重度肾功能不全及需要透析的终末期肾病患者时需要根据肌酐清除率调整剂量；维格列汀在中度或重度肾功能不全或需要接受血液透析治疗的终末期肾病患者中的应用经验有限，因此不推荐此类患者使用；沙格列汀在轻度肾功能不全的患者中无需调整剂量，中重度肾功能不全的患者应将剂量调整为2.5毫克，每日1次，在重度肾功能不全的患者中临床研究经验有限，因此不推荐使用；利格列汀极少经过肾脏排泄，在不同程度肾功能不全的患者中使用，均不需要调整剂量；阿格列汀在中度肾功能受损患者中使用剂量为推荐剂量减半，重度肾功能受损或终末期肾功能衰竭患者中使用剂量为推荐量的四分之一。在开始使用阿格列汀前应评估肾功能并定期复查。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "A.肾功能不全：西格列汀通过肾脏代谢，用于中、重度肾功能不全及需要透析的终末期肾病患者时需要根据肌酐清除率调整剂量；维格列汀在中度或重度肾功能不全或需要接受血液透析治疗的终末期肾病患者中的应用经验有限，因此不推荐此类患者使用；沙格列汀在轻度肾功能不全的患者中无需调整剂量，中重度肾功能不全的患者应将剂量调整为2.5毫克，每日1次，在重度肾功能不全的患者中临床研究经验有限，因此不推荐使用；利格列汀极少经过肾脏排泄，在不同程度肾功能不全的患者中使用，均不需要调整剂量；阿格列汀在中度肾功能受损患者中使用剂量为推荐剂量减半，重度肾功能受损或终末期肾功能衰竭患者中使用剂量为推荐量的四分之一。",
          "start_idx": 0,
          "end_idx": 293,
          "entities": [
            {
              "entity_id": "T557",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 2,
              "end_idx": 7
            },
            {
              "entity_id": "T558",
              "entity": "肾病",
              "entity_type": "Disease",
              "start_idx": 39,
              "end_idx": 41
            },
            {
              "entity_id": "T559",
              "entity": "肾病",
              "entity_type": "Disease",
              "start_idx": 88,
              "end_idx": 90
            },
            {
              "entity_id": "T560",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 212,
              "end_idx": 217
            },
            {
              "entity_id": "T561",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 25,
              "end_idx": 30
            },
            {
              "entity_id": "T562",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 68,
              "end_idx": 73
            },
            {
              "entity_id": "T563",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 120,
              "end_idx": 125
            },
            {
              "entity_id": "T564",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 139,
              "end_idx": 144
            },
            {
              "entity_id": "T565",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 168,
              "end_idx": 173
            },
            {
              "entity_id": "T566",
              "entity": "肾功能受损",
              "entity_type": "Disease",
              "start_idx": 240,
              "end_idx": 245
            },
            {
              "entity_id": "T567",
              "entity": "肾功能受损",
              "entity_type": "Disease",
              "start_idx": 262,
              "end_idx": 267
            },
            {
              "entity_id": "T568",
              "entity": "肾功能衰竭",
              "entity_type": "Disease",
              "start_idx": 271,
              "end_idx": 276
            },
            {
              "entity_id": "T569",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 2,
              "end_idx": 3
            },
            {
              "entity_id": "T570",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 25,
              "end_idx": 26
            },
            {
              "entity_id": "T571",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 39,
              "end_idx": 40
            },
            {
              "entity_id": "T572",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 68,
              "end_idx": 69
            },
            {
              "entity_id": "T573",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 88,
              "end_idx": 89
            },
            {
              "entity_id": "T574",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 120,
              "end_idx": 121
            },
            {
              "entity_id": "T575",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 139,
              "end_idx": 140
            },
            {
              "entity_id": "T576",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 168,
              "end_idx": 169
            },
            {
              "entity_id": "T577",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 212,
              "end_idx": 213
            },
            {
              "entity_id": "T578",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 240,
              "end_idx": 241
            },
            {
              "entity_id": "T579",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 262,
              "end_idx": 263
            },
            {
              "entity_id": "T580",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 271,
              "end_idx": 272
            },
            {
              "entity_id": "T581",
              "entity": "西格列汀",
              "entity_type": "Drug",
              "start_idx": 8,
              "end_idx": 12
            },
            {
              "entity_id": "T582",
              "entity": "维格列汀",
              "entity_type": "Drug",
              "start_idx": 58,
              "end_idx": 62
            },
            {
              "entity_id": "T583",
              "entity": "沙格列汀",
              "entity_type": "Drug",
              "start_idx": 113,
              "end_idx": 117
            },
            {
              "entity_id": "T584",
              "entity": "利格列汀",
              "entity_type": "Drug",
              "start_idx": 194,
              "end_idx": 198
            },
            {
              "entity_id": "T585",
              "entity": "阿格列汀",
              "entity_type": "Drug",
              "start_idx": 233,
              "end_idx": 237
            },
            {
              "entity_id": "T587",
              "entity": "中、重度",
              "entity_type": "Level",
              "start_idx": 21,
              "end_idx": 25
            },
            {
              "entity_id": "T588",
              "entity": "中度",
              "entity_type": "Level",
              "start_idx": 63,
              "end_idx": 65
            },
            {
              "entity_id": "T589",
              "entity": "重度",
              "entity_type": "Level",
              "start_idx": 66,
              "end_idx": 68
            },
            {
              "entity_id": "T590",
              "entity": "轻度",
              "entity_type": "Level",
              "start_idx": 118,
              "end_idx": 120
            },
            {
              "entity_id": "T591",
              "entity": "中重度",
              "entity_type": "Level",
              "start_idx": 136,
              "end_idx": 139
            },
            {
              "entity_id": "T592",
              "entity": "重度",
              "entity_type": "Level",
              "start_idx": 166,
              "end_idx": 168
            },
            {
              "entity_id": "T593",
              "entity": "中度",
              "entity_type": "Level",
              "start_idx": 238,
              "end_idx": 240
            },
            {
              "entity_id": "T594",
              "entity": "重度",
              "entity_type": "Level",
              "start_idx": 260,
              "end_idx": 262
            },
            {
              "entity_id": "T595",
              "entity": "终末期",
              "entity_type": "Class",
              "start_idx": 36,
              "end_idx": 39
            },
            {
              "entity_id": "T596",
              "entity": "终末期",
              "entity_type": "Class",
              "start_idx": 85,
              "end_idx": 88
            },
            {
              "entity_id": "T597",
              "entity": "终末期",
              "entity_type": "Class",
              "start_idx": 268,
              "end_idx": 271
            },
            {
              "entity_id": "T598",
              "entity": "终末期",
              "entity_type": "Class",
              "start_idx": 36,
              "end_idx": 39
            },
            {
              "entity_id": "T599",
              "entity": "肌酐清除率",
              "entity_type": "Test_items",
              "start_idx": 48,
              "end_idx": 53
            },
            {
              "entity_id": "T600",
              "entity": "透析",
              "entity_type": "Treatment",
              "start_idx": 33,
              "end_idx": 35
            },
            {
              "entity_id": "T601",
              "entity": "血液透析",
              "entity_type": "Treatment",
              "start_idx": 78,
              "end_idx": 82
            },
            {
              "entity_id": "T602",
              "entity": "2.5毫克",
              "entity_type": "Amount",
              "start_idx": 154,
              "end_idx": 159
            },
            {
              "entity_id": "T603",
              "entity": "每日1次",
              "entity_type": "Frequency",
              "start_idx": 160,
              "end_idx": 164
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R199",
              "head_entity_id": "T569",
              "tail_entity_id": "T557"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R200",
              "head_entity_id": "T581",
              "tail_entity_id": "T557"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R201",
              "head_entity_id": "T599",
              "tail_entity_id": "T557"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R202",
              "head_entity_id": "T571",
              "tail_entity_id": "T558"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R203",
              "head_entity_id": "T581",
              "tail_entity_id": "T558"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R204",
              "head_entity_id": "T598",
              "tail_entity_id": "T558"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R205",
              "head_entity_id": "T599",
              "tail_entity_id": "T558"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R206",
              "head_entity_id": "T600",
              "tail_entity_id": "T558"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R207",
              "head_entity_id": "T573",
              "tail_entity_id": "T559"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R208",
              "head_entity_id": "T596",
              "tail_entity_id": "T559"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R209",
              "head_entity_id": "T601",
              "tail_entity_id": "T559"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R210",
              "head_entity_id": "T577",
              "tail_entity_id": "T560"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R211",
              "head_entity_id": "T584",
              "tail_entity_id": "T560"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R212",
              "head_entity_id": "T570",
              "tail_entity_id": "T561"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R213",
              "head_entity_id": "T581",
              "tail_entity_id": "T561"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R214",
              "head_entity_id": "T599",
              "tail_entity_id": "T561"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R215",
              "head_entity_id": "T572",
              "tail_entity_id": "T562"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R216",
              "head_entity_id": "T574",
              "tail_entity_id": "T563"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R217",
              "head_entity_id": "T583",
              "tail_entity_id": "T563"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R218",
              "head_entity_id": "T575",
              "tail_entity_id": "T564"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R219",
              "head_entity_id": "T583",
              "tail_entity_id": "T564"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R220",
              "head_entity_id": "T576",
              "tail_entity_id": "T565"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R221",
              "head_entity_id": "T578",
              "tail_entity_id": "T566"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R222",
              "head_entity_id": "T585",
              "tail_entity_id": "T566"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R223",
              "head_entity_id": "T579",
              "tail_entity_id": "T567"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R224",
              "head_entity_id": "T585",
              "tail_entity_id": "T567"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R225",
              "head_entity_id": "T580",
              "tail_entity_id": "T568"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R226",
              "head_entity_id": "T585",
              "tail_entity_id": "T568"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R227",
              "head_entity_id": "T597",
              "tail_entity_id": "T568"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R228",
              "head_entity_id": "T602",
              "tail_entity_id": "T583"
            },
            {
              "relation_type": "Frequency_Drug",
              "relation_id": "R229",
              "head_entity_id": "T603",
              "tail_entity_id": "T583"
            }
          ]
        },
        {
          "sentence_id": "1",
          "sentence": "在开始使用阿格列汀前应评估肾功能并定期复查。",
          "start_idx": 293,
          "end_idx": 315,
          "entities": [
            {
              "entity_id": "T586",
              "entity": "阿格列汀",
              "entity_type": "Drug",
              "start_idx": 5,
              "end_idx": 9
            }
          ],
          "relations": []
        }
      ]
    }
  ]
}